Years 1-5 (2001-2006) Journal Articles

  1. Abbott DE, Pritchard C, Clegg NJ, Ferguson C, Dumpit R, Sikes RA, Nelson PS. Expressed sequence tag profiling identifies developmental and anatomic partitioning of gene expression in the mouse prostate. Genome Biol 2003;4(12):R79.
  2. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Research 2002 Jul;62(13):3609-14.
  3. Adams G, Mitchell A, Ravichandran R, Beer TM, Garzotto M. Metastatic adenocarcinoma of prostate in a healing sternotomy site. Urology 2006 Jul;68(1):204.e13-5.
  4. Adams KF, Chen C, Newton KM, Potter JD, Lampe JW. Soy isoflavones do not modulate prostate-specific antigen concentrations in older men in a randomized controlled trial. Cancer Epidemiology, Biomarkers and Prevention 2004 Apr;13(4):644-8.
  5. Agalliu I, Langeberg WJ, Lampe JW, Salinas CA, Stanford JL. Glutathione S-transferase M1, T1, and P1 polymorphisms and prostate cancer risk in middle-aged men. Prostate 2006 Feb;66(2):146-56.
  6. Agalliu I, Lin DW, Salinas CA, Feng Z, Stanford JL. Polymorphisms in the glutathione S-transferase M(1), T(1), and P(1) genes and prostate cancer prognosis. Prostate 2006 Oct;66(14):1535-41.
  7. Aigner A, Renneberg H, Bojunga J, Apel J, Nelson PS, Czubayko F. Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo. Oncogene 2002 Aug;21(37):5733-42.
  8. Akalin A, Elmore LW, Forsythe HL, Amaker BA, McCollum ED, Nelson PS, Ware JL, Holt SE. A novel mechanism for chaperone-mediated telomerase regulation during prostate cancer progression. Cancer Research 2001 Jun;61(12):4791-6.
  9. Akaza H, Miyanaga N, Takashima N, Naito S, Hirao Y, Tsukamoto T, Fujioka T, Mori M, Kim WJ, Song JM, Pantuck AJ. Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Japanese Journal of Clinical Oncology 2004 Feb;34(2):86-9.
  10. Akaza H, Miyanaga N, Takashima N, Naito S, Hirao Y, Tsukamoto T, Mori M. Is daidzein non-metabolizer a high risk for prostate cancer? A case-controlled study of serum soybean isoflavone concentration. Japanese Journal of Clinical Oncology 2002 Aug;32(8):296-300.
  11. Allen ZA, Merrick GS, Butler WM, Wallner KE, Kurko B, Anderson RL, Murray BC, Galbreath RW. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. International Journal of Radiation Oncology, Biology, Physics 2005 Jul;62(4):981-7.
  12. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. Journal of Clinical Endocrinology and Metabolism 2004 Feb;89(2):503-10.
  13. Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C, Russell D, Tindall D. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. Journal of Urology 2004 Oct;172(4 Pt 1):1399-403.
  14. Andriole GL, Humphrey P, Ray P, Gleave ME, Trachtenberg J, Thomas LN, Lazier CB, Rittmaster RS. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. Journal of Urology 2004 Sep;172(3):915-9.
  15. Baek SH, Ohgi KA, Nelson CA, Welsbie D, Chen C, Sawyers CL, Rose DW, Rosenfeld MG. Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America 2006 Feb;103(9):3100-5.
  16. Baillargeon J, Pollock BH, Kristal AR, Bradshaw P, Hernandez J, Basler J, Higgins B, Lynch S, Rozanski T, Troyer D, Thompson I. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 2005 Mar;103(5):1092-5.
  17. Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, Nelson PS. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Research 2006 Jan;66(2):794-802.
  18. Bayne A, Barry JM, Garzotto M. Radical retropubic prostatectomy after orthotopic liver transplantation. Urology 2005 Jan;65(1):175.
  19. Beekman M, Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW. Selecting patients with pretreatment postvoid residual urine volume less than 100 mL may favorably influence brachytherapy-related urinary morbidity. Urology 2005 Dec;66(6):1266-70.
  20. Beer TM. Preventing prostate cancer. Finasteride shrinks enlarged prostates and may prevent some cases of prostate cancer. But it’s no panacea. Health News 2003 Aug;9(8):1-2.
  21. Beer TM. Development of weekly high-dose calcitriol based therapy for prostate cancer. Urol Oncol 2003 Sep-2003 Oct;21(5):399-405.
  22. Beer TM. ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere. BJU International 2005 Sep;96(4):508-13.
  23. Beer TM, Berry W, Wersinger EM, Bland LB. Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years. Clin Prostate Cancer 2003 Dec;2(3):167-72.
  24. Beer TM, Bland LB, Bussiere JR, Neiss MB, Wersinger EM, Garzotto M, Ryan CW, Janowsky JS. Testosterone loss and estradiol administration modify memory in men. Journal of Urology 2006 Jan;175(1):130-5.
  25. Beer TM, Bubalo JS. Complications of chemotherapy for prostate cancer. Seminars in Urologic Oncology 2001 Aug;19(3):222-30.
  26. Beer TM, Bubalo JS. Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer. Curr Urol Rep 2002 Jun;3(3):232-8.
  27. Beer TM, Bubalo JS. Prevention and management of prostate cancer chemotherapy complications. Urologic Clinics of North America 2004 May;31(2):367-78.
  28. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. Journal of Clinical Oncology 2003 Jan;21(1):123-8.
  29. Beer TM, Eilers KM, Garzotto M, Hsieh YC, Mori M. Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma. Cancer 2004 Feb;100(4):758-63.
  30. Beer TM, El-Geneidi M, Eilers KM. Docetaxel (taxotere) in the treatment of prostate cancer. Expert Rev Anticancer Ther 2003 Jun;3(3):261-8.
  31. Beer TM, Evans AJ, Hough KM, Lowe BA, McWilliams JE, Henner WD. Polymorphisms of GSTP1 and related genes and prostate cancer risk. Prostate Cancer Prostatic Dis 2002;5(1):22-7.
  32. Beer TM, Garzotto M, Eilers KM, Lemmon D. Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy. Journal of Urology 2003 May;169(5):1738-41.
  33. Beer TM, Garzotto M, Eilers KM, Lemmon D, Wersinger EM. Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy. Urology 2004 Feb;63(2):342-7.
  34. Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. British Journal of Cancer 2003 Sep;89(6):968-70.
  35. Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. British Journal of Cancer 2004 Oct;91(8):1425-7.
  36. Beer TM, Garzotto M, Katovic NM. High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer. American Journal of Clinical Oncology 2004 Oct;27(5):535-41.
  37. Beer TM, Garzotto M, Lowe BA, Ellis WJ, Montalto MA, Lange PH, Higano CS. Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer. Clinical Cancer Research 2004 Feb;10(4):1306-11.
  38. Beer TM, Garzotto M, Park B, Mori M, Myrthue A, Janeba N, Sauer D, Eilers K. Effect of calcitriol on prostate-specific antigen in vitro and in humans. Clinical Cancer Research 2006 May;12(9):2812-6.
  39. Beer TM, Hough KM, Garzotto M, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Seminars in Oncology 2001 Aug;28(4 Suppl 15):49-55.
  40. Beer TM, Lemmon D, Lowe BA, Henner WD. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 2003 Mar;97(5):1217-24.
  41. Beer TM, Myrthue A. Calcitriol in cancer treatment: from the lab to the clinic. Mol Cancer Ther 2004 Mar;3(3):373-81.
  42. Beer TM, Myrthue A. Calcitriol in the treatment of prostate cancer. Anticancer Research 2006 Jul-2006 Aug;26(4A):2647-51.
  43. Beer TM, Myrthue A, Eilers KM. Rationale for the development and current status of calcitriol in androgen-independent prostate cancer. World Journal of Urology 2005 Feb;23(1):28-32.
  44. Beer TM, Myrthue A, Garzotto M, O’hara MF, Chin R, Lowe BA, Montalto MA, Corless CL, Henner WD. Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy. Cancer Epidemiology, Biomarkers and Prevention 2004 Dec;13(12):2225-32.
  45. Beer TM, Pierce WC, Lowe BA, Henner WD. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Annals of Oncology 2001 Sep;12(9):1273-9.
  46. Beer TM, Tangen CM, Bland LB, Hussain M, Goldman BH, DeLoughery TG, Crawford ED. The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894. Cancer 2006 Aug;107(3):489-96.
  47. Beer TM, Tangen CM, Bland LB, Thompson IM, Crawford ED. Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of southwest oncology group study 8894. Journal of Urology 2004 Dec;172(6 Pt 1):2213-7.
  48. Bermejo C, Kristal AR, Zeliadt SB, Ramsey S, Thompson IM. Localized prostate cancer: quality of life meets Whitmore’s legacy. Journal of the National Cancer Institute 2004 Sep;96(18):1348-9.
  49. Berry DL, Ellis WJ, Woods NF, Schwien C, Mullen KH, Yang C. Treatment decision-making by men with localized prostate cancer: the influence of personal factors. Urol Oncol 2003 Mar-2003 Apr;21(2):93-100.
  50. Bertram J, Peacock JW, Fazli L, Mui AL, Chung SW, Cox ME, Monia B, Gleave ME, Ong CJ. Loss of PTEN is associated with progression to androgen independence. Prostate 2006 Jun;66(9):895-902.
  51. Bertram J, Peacock JW, Tan C, Mui AL, Chung SW, Gleave ME, Dedhar S, Cox ME, Ong CJ. Inhibition of the phosphatidylinositol 3′-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells. Cancer Research 2006 May;66(9):4781-8.
  52. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2006 Jun;91(6):1995-2010.
  53. Bland LB, Garzotto M, DeLoughery TG, Ryan CW, Schuff KG, Wersinger EM, Lemmon D, Beer TM. Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer 2005 Feb;103(4):717-23.
  54. Bok RA, Hansell EJ, Nguyen TP, Greenberg NM, McKerrow JH, Shuman MA. Patterns of protease production during prostate cancer progression: proteomic evidence for cascades in a transgenic model. Prostate Cancer Prostatic Dis 2003;6(4):272-80.
  55. Bonham M, Arnold H, Montgomery B, Nelson PS. Molecular effects of the herbal compound PC-SPES: identification of activity pathways in prostate carcinoma. Cancer Research 2002 Jul;62(14):3920-4.
  56. Bonham M, Posakony J, Coleman I, Montgomery B, Simon J, Nelson PS. Characterization of chemical constituents in Scutellaria baicalensis with antiandrogenic and growth-inhibitory activities toward prostate carcinoma. Clinical Cancer Research 2005 May;11(10):3905-14.
  57. Bonham MJ, Galkin A, Montgomery B, Stahl WL, Agus D, Nelson PS. Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition. Journal of the National Cancer Institute 2002 Nov;94(21):1641-7.
  58. Bott SR, Henderson A, Laing RW, Montgomery BS, Langley SE. Technical considerations when obtaining and interpreting prostatic biopsies from men with a suspicion of early prostate cancer. BJU International 2005 Sep;96(4):686.
  59. Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M, Vessella RL. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 2001 Apr;57(4):611-6.
  60. Brown JM, Vessella RL, Kostenuik PJ, Dunstan CR, Lange PH, Corey E. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clinical Cancer Research 2001 Oct;7(10):2977-83.
  61. Brubaker KD, Brown LG, Vessella RL, Corey E. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 2006;6:15.
  62. Brubaker KD, Corey E, Brown LG, Vessella RL. Bone morphogenetic protein signaling in prostate cancer cell lines. Journal of Cellular Biochemistry 2004 Jan;91(1):151-60.
  63. Brubaker KD, Vessella RL, Brown LG, Corey E. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 2003 Jun;56(1):13-22.
  64. Brubaker KD, Vessella RL, True LD, Thomas R, Corey E. Cathepsin K mRNA and protein expression in prostate cancer progression. Journal of Bone and Mineral Research 2003 Feb;18(2):222-30.
  65. Bruchovsky N, Klotz L, Crook J, Malone S, Ludgate C, Morris WJ, Gleave ME, Goldenberg SL. Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters. Cancer 2006 Jul;107(2):389-95.
  66. Bussiere JR, Beer TM, Neiss MB, Janowsky JS. Androgen deprivation impairs memory in older men. Behavioral Neuroscience 2005 Dec;119(6):1429-37.
  67. Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. Journal of Clinical Oncology 2005 Jan;23(3):455-60.
  68. Carroll PR, Benaron DA, Blackledge G, Coakley FV, D’Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M 3rd, Sellers WR, Smith MR, McMann MC, Kantoff PW. Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. Journal of Urology 2003 Dec;170(6 Pt 2):S3-5.
  69. Carroll PR, Chan JM, D’Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, Xu J, McMann MC, Kantoff PW. Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. Journal of Urology 2004 Nov;172(5 Pt 2):S3-5.
  70. Chaib H, MacDonald JW, Vessella RL, Washburn JG, Quinn JE, Odman A, Rubin MA, Macoska JA. Haploinsufficiency and reduced expression of genes localized to the 8p chromosomal region in human prostate tumors. Genes, Chromosomes and Cancer 2003 Jul;37(3):306-13.
  71. Chang SS, Benson MC, Campbell SC, Crook J, Dreicer R, Evans CP, Hall MC, Higano C, Kelly WK, Sartor O, Smith JA Jr. Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma. Cancer 2005 Jan;103(1):11-21.
  72. Chen C. Risk of prostate cancer in relation to polymorphisms of metabolic genes. Epidemiologic Reviews 2001;23(1):30-5.
  73. Chen C, Bhalala HV, Vessella RL, Dong JT. KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer. Prostate 2003 May;55(2):81-8.
  74. Chen C, Hyytinen ER, Sun X, Helin HJ, Koivisto PA, Frierson HF Jr, Vessella RL, Dong JT. Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. American Journal of Pathology 2003 Apr;162(4):1349-54.
  75. Chen C, Lamharzi N, Weiss NS, Etzioni R, Dightman DA, Barnett M, DiTommaso D, Goodman G. Androgen receptor polymorphisms and the incidence of prostate cancer. Cancer Epidemiology, Biomarkers and Prevention 2002 Oct;11(10 Pt 1):1033-40.
  76. Chen C, Lewis SK, Voigt L, Fitzpatrick A, Plymate SR, Weiss NS. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 2005 Jan;103(1):76-84.
  77. Chen C, Weiss NS, Stanczyk FZ, Lewis SK, DiTommaso D, Etzioni R, Barnett MJ, Goodman GE. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiology, Biomarkers and Prevention 2003 Dec;12(12):1410-6.
  78. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 2004 Jan;10(1):33-9.
  79. Chen D, Adenekan B, Chen L, Vaughan ED, Gerald W, Feng Z, Knudsen BS. Syndecan-1 expression in locally invasive and metastatic prostate cancer. Urology 2004 Feb;63(2):402-7.
  80. Chen Q, Watson JT, Marengo SR, Decker KS, Coleman I, Nelson PS, Sikes RA. Gene expression in the LNCaP human prostate cancer progression model: Progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo. Cancer Letters 2006 Feb.
  81. Cherrier MM, Matsumoto AM, Amory JK, Ahmed S, Bremner W, Peskind ER, Raskind MA, Johnson M, Craft S. The role of aromatization in testosterone supplementation: effects on cognition in older men. Neurology 2005 Jan;64(2):290-6.
  82. Cherrier MM, Matsumoto AM, Amory JK, Asthana S, Bremner W, Peskind ER, Raskind MA, Craft S. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology 2005 Jun;64(12):2063-8.
  83. Cherrier MM, Rose AL, Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. Journal of Urology 2003 Nov;170(5):1808-11.
  84. Cheteri MB, Stanford JL, Friedrichsen DM, Peters MA, Iwasaki L, Langlois MC, Feng Z, Ostrander EA. Vitamin D receptor gene polymorphisms and prostate cancer risk. Prostate 2004 Jun;59(4):409-18.
  85. Cheung PK, Woolcock B, Adomat H, Sutcliffe M, Bainbridge TC, Jones EC, Webber D, Kinahan T, Sadar M, Gleave ME, Vielkind J. Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Research 2004 Sep;64(17):5929-33.
  86. Chi KN. Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer. World Journal of Urology 2005 Feb;23(1):33-7.
  87. Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D, Gleave ME. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. Journal of the National Cancer Institute 2005 Sep;97(17):1287-96.
  88. Chi KN, Gleave ME. Antisense approaches in prostate cancer. Expert Opin Biol Ther 2004 Jun;4(6):927-36.
  89. Chi KN, Gleave ME, Klasa R, Murray N, Bryce C, Lopes de Menezes DE, D’Aloisio S, Tolcher AW. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clinical Cancer Research 2001 Dec;7(12):3920-7.
  90. Choi S, Wallner KE, Merrick GS, Cavanagh W, Butler WM. Treatment margins predict biochemical outcomes after prostate brachytherapy. Cancer J 2004 May-2004 Jun;10(3):175-80.
  91. Chong KT, Hampson NB, Bostwick DG, Vessella RL, Corman JM. Hyperbaric oxygen does not accelerate latent in vivo prostate cancer: implications for the treatment of radiation-induced haemorrhagic cystitis. BJU International 2004 Dec;94(9):1275-8.
  92. Chou SF, Chen CY. Production of monoclonal and polyclonal antibodies against prostate-specific antigen, a prostate cancer serum marker. Hybrid Hybridomics 2004 Feb;23(1):73-7.
  93. Clegg LX, Potosky AL, Harlan LC, Hankey BF, Hoffman RM, Stanford JL, Hamilton AS. Comparison of self-reported initial treatment with medical records: results from the prostate cancer outcomes study. American Journal of Epidemiology 2001 Sep;154(6):582-7.
  94. Clegg N, Abbott D, Ferguson C, Coleman R, Nelson PS. Characterization and comparative analyses of transcriptomes from the normal and neoplastic human prostate. Prostate 2004 Aug;60(3):227-39.
  95. Clegg N, Eroglu B, Ferguson C, Arnold H, Moorman A, Nelson PS. Digital expression profiles of the prostate androgen-response program. Journal of Steroid Biochemistry and Molecular Biology 2002 Jan;80(1):13-23.
  96. Clegg N, Ferguson C, True LD, Arnold H, Moorman A, Quinn JE, Vessella RL, Nelson PS. Molecular characterization of prostatic small-cell neuroendocrine carcinoma. Prostate 2003 Apr;55(1):55-64.
  97. Conlon EM, Goode EL, Gibbs M, Stanford JL, Badzioch M, Janer M, Kolb S, Hood L, Ostrander EA, Jarvik GP, Wijsman EM. Oligogenic segregation analysis of hereditary prostate cancer pedigrees: evidence for multiple loci affecting age at onset. International Journal of Cancer 2003 Jul;105(5):630-5.
  98. Cooley J, Takayama TK, Shapiro SD, Schechter NM, Remold-O’Donnell E. The serpin MNEI inhibits elastase-like and chymotrypsin-like serine proteases through efficient reactions at two active sites. Biochemistry 2001 Dec;40(51):15762-70.
  99. Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TE, Blair JM, Vessella RL. Osteoprotegerin in prostate cancer bone metastasis. Cancer Research 2005 Mar;65(5):1710-8.
  100. Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clinical Cancer Research 2003 Jan;9(1):295-306.
  101. Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 2002 Jun;52(1):20-33.
  102. Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, Vessella RL. LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate 2003 Jun;55(4):239-46.
  103. Corey E, Quinn JE, Emond MJ, Buhler KR, Brown LG, Vessella RL. Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol. Clinical Cancer Research 2002 Apr;8(4):1003-7.
  104. Corey E, Quinn JE, Vessella RL. A novel method of generating prostate cancer metastases from orthotopic implants. Prostate 2003 Jul;56(2):110-4.
  105. Cross AJ, Peters U, Kirsh VA, Andriole GL, Reding D, Hayes RB, Sinha R. A prospective study of meat and meat mutagens and prostate cancer risk. Cancer Research 2005 Dec;65(24):11779-84.
  106. Dai J, Shen R, Sumitomo M, Goldberg JS, Geng Y, Navarro D, Xu S, Koutcher JA, Garzotto M, Powell CT, Nanus DM. Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells. Clinical Cancer Research 2001 May;7(5):1370-7.
  107. Damon SE, Plymate SR, Carroll JM, Sprenger CC, Dechsukhum C, Ware JL, Roberts CT Jr. Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. Endocrinology 2001 Jan;142(1):21-7.
  108. Davison BJ, Gleave ME, Goldenberg SL, Degner LF, Hoffart D, Berkowitz J. Assessing information and decision preferences of men with prostate cancer and their partners. Cancer Nursing 2002 Feb;25(1):42-9.
  109. Davison BJ, Goldenberg SL, Gleave ME, Degner LF. Provision of individualized information to men and their partners to facilitate treatment decision making in prostate cancer. Oncology Nursing Forum 2003 Jan-2003 Feb;30(1):107-14.
  110. Degl’Innocenti E, Grioni M, Boni A, Camporeale A, Bertilaccio MT, Freschi M, Monno A, Arcelloni C, Greenberg NM, Bellone M. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. European Journal of Immunology 2005 Jan;35(1):66-75.
  111. Devi GR, Beer TM, Corless CL, Arora V, Weller DL, Iversen PL. In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clinical Cancer Research 2005 May;11(10):3930-8.
  112. Devi GR, Sprenger CC, Plymate SR, Rosenfeld RG. Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo. Prostate 2002 May;51(2):141-52.
  113. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004 Mar;100(5):892-9.
  114. Dong XY, Chen C, Sun X, Guo P, Vessella RL, Wang RX, Chung LW, Zhou W, Dong JT. FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Research 2006 Jul;66(14):6998-7006.
  115. Drivdahl R, Haugk KH, Sprenger CC, Nelson PS, Tennant MK, Plymate SR. Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9. Oncogene 2004 Jun;23(26):4584-93.
  116. Drivdahl RH, Sprenger C, Trimm K, Plymate SR. Inhibition of growth and increased expression of insulin-like growth factor-binding protein-3 (IGFBP-3) and -6 in prostate cancer cells stably transfected with antisense IGFBP-4 complementary deoxyribonucleic acid. Endocrinology 2001 May;142(5):1990-8.
  117. Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C, Wang Z, Gleave ME. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clinical Cancer Research 2005 Jul;11(13):4905-11.
  118. el-Geneidy M, Garzotto M, Panagiotou I, Hsieh YC, Mori M, Peters L, Klein T, Beer TM. Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort. BJU International 2004 Mar;93(4):510-5.
  119. Ellis WJ. Prostate brachytherapy. Cancer and Metastasis Reviews 2002;21(2):125-9.
  120. Ellis WJ, Etzioni R, Vessella RL, Hu C, Goodman GE. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer. Journal of Urology 2001 Jul;166(1):93-8; discussion 98-9.
  121. Ellis WJ, Pfitzenmaier J, Colli J, Arfman E, Lange PH, Vessella RL. Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology 2003 Feb;61(2):277-81.
  122. Etminan M, FitzGerald JM, Gleave M, Chambers K. Intake of selenium in the prevention of prostate cancer: a systematic review and meta-analysis. Cancer Causes and Control 2005 Nov;16(9):1125-31.
  123. Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME, Nelson CC. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Research 2004 Mar;64(6):2212-21.
  124. Etzioni R, Berry KM, Legler JM, Shaw P. Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998. Urology 2002 Feb;59(2):251-5.
  125. Etzioni R, Falcon S, Gann PH, Kooperberg CL, Penson DF, Stampfer MJ. Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection? Cancer Epidemiology, Biomarkers and Prevention 2004 Oct;13(10):1640-5.
  126. Etzioni R, Hawley S, Billheimer D, True LD, Knudsen B. Analyzing patterns of staining in immunohistochemical studies: application to a study of prostate cancer recurrence. Cancer Epidemiology, Biomarkers and Prevention 2005 May;14(5):1040-6.
  127. Etzioni R, Kooperberg C, Pepe M, Smith R, Gann PH. Combining biomarkers to detect disease with application to prostate cancer. Biostatistics 2003 Oct;4(4):523-38.
  128. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. Journal of the National Cancer Institute 2002 Jul;94(13):981-90.
  129. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G, Hartwell L. The case for early detection. Nat Rev Cancer 2003 Apr;3(4):243-52.
  130. Etzioni RD, Howlader N, Shaw PA, Ankerst DP, Penson DF, Goodman PJ, Thompson IM. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. Journal of Urology 2005 Sep;174(3):877-81.
  131. Evangelou AI, Winter SF, Huss WJ, Bok RA, Greenberg NM. Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype. Journal of Cellular Biochemistry 2004 Mar;91(4):671-83.
  132. Ewart-Toland A, Dai Q, Gao YT, Nagase H, Dunlop MG, Farrington SM, Barnetson RA, Anton-Culver H, Peel D, Ziogas A, Lin D, Miao X, Sun T, Ostrander EA, Stanford JL, Langlois M, Chan JM, Yuan J, Harris CC, Bowman ED, Clayman GL, Lippman SM, Lee JJ, Zheng W, Balmain A. Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis 2005 Aug;26(8):1368-73.
  133. Fedoruk MN, Gimenez-Bonafe P, Guns ES, Mayer LD, Nelson CC. P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate 2004 Apr;59(1):77-90.
  134. Feuer EJ, Etzioni R, Cronin KA, Mariotto A. The use of modeling to understand the impact of screening on U.S. mortality: examples from mammography and PSA testing. Statistical Methods in Medical Research 2004 Dec;13(6):421-42.
  135. Figueiredo KA, Palmer JB, Mui AL, Nelson CC, Cox ME. Demonstration of upregulated H2 relaxin mRNA expression during neuroendocrine differentiation of LNCaP prostate cancer cells and production of biologically active mammalian recombinant 6 histidine-tagged H2 relaxin. Annals of the New York Academy of Sciences 2005 May;1041:320-7.
  136. Fink D, Fazli L, Aronow B, Gleave ME, Ong CJ. Clusterin is not essential for androgen-regulated involution and regeneration of the normal mouse prostate. Prostate 2006 Sep;66(13):1445-54.
  137. Fleshner N, Dranitsaris G, Finelli A, Tsihlias J, Bell D, Gleave M. Surgical wait times for patients with urological cancers: a survey of Canadian surgeons. Can J Urol 2006 Jun;13 Suppl 3:3-13.
    CORPORATE NAME: Canadian surgical wait times (SWAT) initiative.
  138. Fraser MM, Watson PM, Fraig MM, Kelley JR, Nelson PS, Boylan AM, Cole DJ, Watson DK. CaSm-mediated cellular transformation is associated with altered gene expression and messenger RNA stability. Cancer Research 2005 Jul;65(14):6228-36.
  139. Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso CL, Palotie AV, Belldegrun AS. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate 2003 Apr;55(1):71-80.
  140. Freeman KW, Gangula RD, Welm BE, Ozen M, Foster BA, Rosen JM, Ittmann M, Greenberg NM, Spencer DM. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. Cancer Research 2003 Oct;63(19):6237-43.
  141. Freeman KW, Welm BE, Gangula RD, Rosen JM, Ittmann M, Greenberg NM, Spencer DM. Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Research 2003 Dec;63(23):8256-63.
  142. Friedrichsen DM, Hawley S, Shu J, Humphrey M, Sabacan L, Iwasaki L, Etzioni R, Ostrander EA, Stanford JL. IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer. Prostate 2005 Sep;65(1):44-51.
  143. Friedrichsen DM, Stanford JL, Isaacs SD, Janer M, Chang BL, Deutsch K, Gillanders E, Kolb S, Wiley KE, Badzioch MD, Zheng SL, Walsh PC, Jarvik GP, Hood L, Trent JM, Isaacs WB, Ostrander EA, Xu J. Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families. Proceedings of the National Academy of Sciences of the United States of America 2004 Feb;101(7):1939-44.
  144. Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. Journal of Clinical Oncology 2004 Sep;22(17):3485-90.
  145. Garzotto M, Beer TM. Syndrome of inappropriate antidiuretic hormone secretion: a rare complication of prostate cancer. Journal of Urology 2001 Oct;166(4):1386.
  146. Garzotto M, Beer TM, Hudson RG, Peters L, Hsieh YC, Barrera E, Klein T, Mori M. Improved detection of prostate cancer using classification and regression tree analysis. Journal of Clinical Oncology 2005 Jul;23(19):4322-9.
  147. Garzotto M, Hudson RG, Peters L, Hsieh YC, Barrera E, Mori M, Beer TM, Klein T. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL. Cancer 2003 Oct;98(7):1417-22.
  148. Garzotto M, Myrthue A, Higano CS, Beer TM. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urol Oncol 2006 May-2006 Jun;24(3):254-9.
  149. Garzotto M, Park Y, Mongoue-Tchokote S, Bledsoe J, Peters L, Blank BH, Austin D, Beer TM, Mori M. Recursive partitioning for risk stratification in men undergoing repeat prostate biopsies. Cancer 2005 Nov;104(9):1911-7.
  150. Gaylis FD, Lin DW, Ignatoff JM, Amling CL, Tutrone RF, Cosgrove DJ. Prostate cancer in men using testosterone supplementation. Journal of Urology 2005 Aug;174(2):534-8; discussion 538.
  151. Gelmon KA, Stewart D, Chi KN, Chia S, Cripps C, Huan S, Janke S, Ayers D, Fry D, Shabbits JA, Walsh W, McIntosh L, Seymour LK. A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131. Annals of Oncology 2004 Jul;15(7):1115-22.
  152. Gerstein AV, Almeida TA, Zhao G, Chess E, Shih IeM, Buhler K, Pienta K, Rubin MA, Vessella R, Papadopoulos N. APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes, Chromosomes and Cancer 2002 May;34(1):9-16.
  153. Gimenez-Bonafe P, Fedoruk MN, Whitmore TG, Akbari M, Ralph JL, Ettinger S, Gleave ME, Nelson CC. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 2004 May;59(3):337-49.
  154. Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. Journal of Urology 2003 Jan;169(1):164-9.
  155. Gleave M, Chi KN. Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers. Annals of the New York Academy of Sciences 2005 Nov;1058:1-15.
  156. Gleave M, Evans C. What’s hot in the prostate? Prostate Cancer Prostatic Dis 2002;5(3):168-71.
  157. Gleave M, Evans CP. What’s hot in the prostate? Prostate Cancer Prostatic Dis 2003;6(4):268-71.
  158. Gleave M, Evans CP. What’s hot in the prostate? Prostate Cancer Prostatic Dis 2004;7(4):273-6.
  159. Gleave M, Jansen B. Clusterin and IGFBPs as antisense targets in prostate cancer. Annals of the New York Academy of Sciences 2003 Dec;1002:95-104.
  160. Gleave M, Kelly WK. High-risk localized prostate cancer: a case for early chemotherapy. Journal of Clinical Oncology 2005 Nov;23(32):8186-91.
  161. Gleave M, Miyake H. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World Journal of Urology 2005 Feb;23(1):38-46.
  162. Gleave M, Miyake H, Chi K. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. Cancer Chemotherapy and Pharmacology 2005 Nov;56 Suppl 1:47-57.
  163. Gleave M, Miyake H, Zangemeister-Wittke U, Jansen B. Antisense therapy: current status in prostate cancer and other malignancies. Cancer and Metastasis Reviews 2002;21(1):79-92.
  164. Gleave M, Nelson C, Chi K. Antisense targets to enhance hormone and cytotoxic therapies in advanced prostate cancer. Curr Drug Targets 2003 Apr;4(3):209-21.
  165. Gleave M, Qian J, Andreou C, Pommerville P, Chin J, Casey R, Steinhoff G, Fleshner N, Bostwick D, Thomas L, Rittmaster R. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer-results from a 4-month pre-radical prostatectomy study. Prostate 2006 Nov 1;66(15):1674-85
  166. Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, Jewett M, Kassabian V, Chetner M, Dupont C, Van Rensselaer S. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. Journal of Urology 2001 Aug;166(2):500-6; discussion 506-7.
  167. Gleave ME, Miyake H, Zellweger T, Chi K, July L, Nelson C, Rennie P. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology 2001 Aug;58(2 Suppl 1):39-49.
  168. Gleave ME, Zellweger T, Chi K, Miyake H, Kiyama S, July L, Leung S. Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. Investigational New Drugs 2002 May;20(2):145-58.
  169. Gmyrek GA, Walburg M, Webb CP, Yu HM, You X, Vaughan ED, Vande Woude GF, Knudsen BS. Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. American Journal of Pathology 2001 Aug;159(2):579-90.
  170. Goel HL, Breen M, Zhang J, Das I, Aznavoorian-Cheshire S, Greenberg NM, Elgavish A, Languino LR. beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts. Cancer Research 2005 Aug;65(15):6692-700.
  171. Gong L, Cho PS, Han BH, Wallner KE, Sutlief SG, Pathak SD, Haynor DR, Kim Y. Ultrasonography and fluoroscopic fusion for prostate brachytherapy dosimetry. International Journal of Radiation Oncology, Biology, Physics 2002 Dec;54(5):1322-30.
  172. Gong Z, Agalliu I, Lin, DW, Stanford JL, Kristal AR. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer, 2007 Mar 15;109(6):1192-202
  173. Goo YA, Goodlett DR, Pascal LE, Worthington KD, Vessella RL, True LD, Liu AY. Stromal mesenchyme cell genes of the human prostate and bladder. BMC Urol 2005;5:17.
  174. Goode EL, Stanford JL, Peters MA, Janer M, Gibbs M, Kolb S, Badzioch MD, Hood L, Ostrander EA, Jarvik GP. Clinical characteristics of prostate cancer in an analysis of linkage to four putative susceptibility loci. Clinical Cancer Research 2001 Sep;7(9):2739-49.
  175. Goodman GE, Schaffer S, Omenn GS, Chen C, King I. The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from beta-carotene and retinol efficacy trial. Cancer Epidemiology, Biomarkers and Prevention 2003 Jun;12(6):518-26.
  176. Goodman PJ, Tangen CM, Crowley JJ, Carlin SM, Ryan A, Coltman CA Jr, Ford LG, Thompson IM. Implementation of the Prostate Cancer Prevention Trial (PCPT). Controlled Clinical Trials 2004 Apr;25(2):203-22.
  177. Goodman PJ, Thompson IM Jr, Tangen CM, Crowley JJ, Ford LG, Coltman CA Jr. The prostate cancer prevention trial: design, biases and interpretation of study results. Journal of Urology 2006 Jun;175(6):2234-42.
  178. Greenberg DL, Mize GJ, Takayama TK. Protease-activated receptor mediated RhoA signaling and cytoskeletal reorganization in LNCaP cells. Biochemistry 2003 Jan;42(3):702-9.
  179. Greenlee H, White E, Patterson RE, Kristal AR. Supplement use among cancer survivors in the Vitamins and Lifestyle (VITAL) study cohort. Journal of Alternative and Complementary Medicine 2004 Aug;10(4):660-6.
  180. Grizzle WE, Adam BL, Bigbee WL, Conrads TP, Carroll C, Feng Z, Izbicka E, Jendoubi M, Johnsey D, Kagan J, Leach RJ, McCarthy DB, Semmes OJ, Srivastava S, Srivastava S, Thompson IM, Thornquist MD, Verma M, Zhang Z, Zou Z. Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer. Disease Markers 2003;19(4-5):185-95.
  181. Grizzle WE, Semmes OJ, Basler J, Izbicka E, Feng Z, Kagan J, Adam BL, Troyer D, Srivastava S, Thornquist M, Zhang Z, Thompson IM. The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology. Urol Oncol 2004 Jul-2004 Aug;22(4):337-43.
  182. Grouse LH, Munson PJ, Nelson PS. Sequence databases and microarrays as tools for identifying prostate cancer biomarkers. Urology 2001 Apr;57(4 Suppl 1):154-9.
  183. Gruenewald DA, Matsumoto AM. Testosterone supplementation therapy for older men: potential benefits and risks. Journal of the American Geriatrics Society 2003 Jan;51(1):101-15; discussion 115.
  184. Gulley JL, Figg WD, Steinberg SM, Carter J, Sartor O, Higano CS, Petrylak DP, Chatta G, Hussain MH, Dahut WL. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. Journal of Urology 2005 May;173(5):1567-71.
  185. Guns ES, Xie X, Fedoruk M, Madera C, Cowell S, Mayer LD, Skov K, Gleave ME, Kozlowski P. pH modulation using CsCl enhances therapeutic effects of vitamin D in LNCaP tumor bearing mice. Prostate 2005 Aug;64(3):316-22.
  186. Gunther S, Patterson RE, Kristal AR, Stratton KL, White E. Demographic and health-related correlates of herbal and specialty supplement use. Journal of the American Dietetic Association 2004 Jan;104(1):27-34.
  187. Guo N, Ye JJ, Liang SJ, Mineo R, Li SL, Giannini S, Plymate SR, Sikes RA, Fujita-Yamaguchi Y. The role of insulin-like growth factor-II in cancer growth and progression evidenced by the use of ribozymes and prostate cancer progression models. Growth Hormone and IGF Research 2003 Feb;13(1):44-53.
  188. Guo X, Knudsen BS, Peehl DM, Ruiz A, Bok D, Rando RR, Rhim JS, Nanus DM, Gudas LJ. Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens. Cancer Research 2002 Mar;62(6):1654-61.
  189. Gustafson MP, Xu C, Grim JE, Clurman BE, Knudsen BS. Regulation of cell proliferation in a stratified culture system of epithelial cells from prostate tissue. Cell and Tissue Research 2006 Aug;325(2):263-76.
  190. Gutman S, Merrick GS, Butler WM, Wallner KE, Allen Z, Galbreath RW, Adamovich E. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy. BJU International 2006 Jan;97(1):62-8.
  191. Gutman SA, Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW, Adamovich E. Temporal relationship between prostate brachytherapy and the diagnosis of colorectal cancer. International Journal of Radiation Oncology, Biology, Physics 2006 Sep;66(1):48-55.
  192. Habel LA, Zhao W, Stanford JL. Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes and Control 2002 Jun;13(5):427-34.
  193. Halvorsen OJ, Oyan AM, Bo TH, Olsen S, Rostad K, Haukaas SA, Bakke AM, Marzolf B, Dimitrov K, Stordrange L, Lin B, Jonassen I, Hood L, Akslen LA, Kalland KH. Gene expression profiles in prostate cancer: association with patient subgroups and tumour differentiation. International Journal of Oncology 2005 Feb;26(2):329-36.
  194. Hamilton AS, Stanford JL, Gilliland FD, Albertsen PC, Stephenson RA, Hoffman RM, Eley JW, Harlan LC, Potosky AL. Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. Journal of Clinical Oncology 2001 May;19(9):2517-26.
  195. Han BH, Demel KC, Wallner K, Ellis W, Young L, Russell K. Patient reported complications after prostate brachytherapy. Journal of Urology 2001 Sep;166(3):953-7.
  196. Han BH, Wallner KE. Dosimetric and radiographic correlates to prostate brachytherapy-related rectal complications. International Journal of Cancer 2001 Dec;96(6):372-8.
  197. Han G, Buchanan G, Ittmann M, Harris JM, Yu X, Demayo FJ, Tilley W, Greenberg NM. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proceedings of the National Academy of Sciences of the United States of America 2005 Jan;102(4):1151-6.
  198. Han G, Miura K, Takayama T, Tsutsui Y. Primary prostatic endodermal sinus tumor (yolk sac tumor) combined with a small focal seminoma. American Journal of Surgical Pathology 2003 Apr;27(4):554-9.
  199. Harlan LC, Potosky A, Gilliland FD, Hoffman R, Albertsen PC, Hamilton AS, Eley JW, Stanford JL, Stephenson RA. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. Journal of the National Cancer Institute 2001 Dec;93(24):1864-71.
  200. Hay RV, Cao B, Skinner RS, Su Y, Zhao P, Gustafson MF, Qian CN, Teh BT, Knudsen BS, Resau JH, Shen S, Waters DJ, Gross MD, Vande Woude GF. Nuclear imaging of Met-expressing human and canine cancer xenografts with radiolabeled monoclonal antibodies (MetSeek). Clinical Cancer Research 2005 Oct;11(19 Pt 2):7064s-9s.
  201. Hay RV, Cao B, Skinner RS, Wang LM, Su Y, Resau JH, Knudsen BS, Gustafson MF, Koo HM, Woude GF, Gross MD. Radioimmunoscintigraphy of human met-expressing tumor xenografts using met3, a new monoclonal antibody. Clinical Cancer Research 2003 Sep;9(10 Pt 2):3839S-44S.
  202. Hayes-Lattin BM, Kovach PA, Henner WD, Beer TM. Successful treatment of metastatic hormone-refractory prostate cancer with malignant pericardial tamponade using docetaxel. Urology 2002 Jan;59(1):137.
  203. Hayes RB, Sigurdson A, Moore L, Peters U, Huang WY, Pinsky P, Reding D, Gelmann EP, Rothman N, Pfeiffer RM, Hoover RN, Berg CD. Methods for etiologic and early marker investigations in the PLCO trial. Mutation Research 2005 Dec;592(1-2):147-54.
  204. He M, Rennie PS, Dragowska V, Nelson CC, Jia W. A mutant P53 can activate apoptosis through a mechanism distinct from those induced by wild type P53. FEBS Letters 2002 Apr;517(1-3):151-4.
  205. Henderson A, Andrich DE, Pietrasik ME, Higgins D, Montgomery B, Langley SE. Outcome analysis and patient satisfaction following octant transrectal ultrasound-guided prostate biopsy: a prospective study comparing consultant urologist, specialist registrar and nurse practitioner in urology. Prostate Cancer Prostatic Dis 2004;7(2):122-5.
  206. Henner WD, Evans AJ, Hough KM, Harris EL, Lowe BA, Beer TM. Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate 2001 Dec;49(4):263-6.
  207. Hernandez I, Maddison LA, Wei Y, DeMayo F, Petras T, Li B, Gingrich JR, Rosen JM, Greenberg NM. Prostate-specific expression of p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival. Mol Cancer Res 2003 Dec;1(14):1036-47.
  208. Higano C. Androgen-deprivation therapy for prostate cancer. Clin Prostate Cancer 2003 Jun;2(1):22-3.
  209. Higano C, Shields A, Wood N, Brown J, Tangen C. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 2004 Dec;64(6):1182-6.
  210. Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003 Feb;61(2 Suppl 1):32-8.
  211. Higano CS. Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. Urol Oncol 2003 Sep-2003 Oct;21(5):392-8.
  212. Higano CS. Management of bone loss in men with prostate cancer. Journal of Urology 2003 Dec;170(6 Pt 2):S59-63; discussion S64.
  213. Higano CS. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urologic Clinics of North America 2004 May;31(2):331-52.
  214. Higano CS. Current status of treatment for patients with metastatic prostate cancer. Can J Urol 2005 Jun;12 Suppl 2:38-41.
  215. Higano CS, Vogelzang NJ, Sosman JA, Feng A, Caron D, Small EJ. Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer. Clinical Cancer Research 2004 Feb;10(4):1219-25.
  216. Hill RE, de Avila DM, Bertrand KP, Greenberg NM, Reeves JJ. Immunization against luteinizing hormone-releasing hormone fusion proteins does not decrease prostate cancer in the transgenic adenocarcinoma mouse prostate model. Exp Biol Med (Maywood) 2003 Jul;228(7):818-22.
  217. Hinerman-Mulroy A, Merrick GS, Butler WM, Wallner KE, Allen Z, Adamovich E. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy. International Journal of Radiation Oncology, Biology, Physics 2004 Aug;59(5):1367-82.
  218. Hochachka PW, Rupert JL, Goldenberg L, Gleave M, Kozlowski P. Going malignant: the hypoxia-cancer connection in the prostate. Bioessays 2002 Aug;24(8):749-57.
  219. Hoffelt SC, Marshall LM, Garzotto M, Hung A, Holland J, Beer TM. A comparison of CT scan to transrectal ultrasound-measured prostate volume in untreated prostate cancer. International Journal of Radiation Oncology, Biology, Physics 2003 Sep;57(1):29-32.
  220. Hoffman RM, Barry MJ, Stanford JL, Hamilton AS, Hunt WC, Collins MM. Health outcomes in older men with localized prostate cancer: results from the Prostate Cancer Outcomes Study. American Journal of Medicine 2006 May;119(5):418-25.
  221. Hoffman RM, Gilliland FD, Eley JW, Harlan LC, Stephenson RA, Stanford JL, Albertson PC, Hamilton AS, Hunt WC, Potosky AL. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. Journal of the National Cancer Institute 2001 Mar;93(5):388-95.
  222. Hood L, Heath JR, Phelps ME, Lin B. Systems biology and new technologies enable predictive and preventative medicine. Science 2004 Oct;306(5696):640-3.
  223. Hoque A, Albanes D, Lippman SM, Spitz MR, Taylor PR, Klein EA, Thompson IM, Goodman P, Stanford JL, Crowley JJ, Coltman CA, Santella RM. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes and Control 2001 Sep;12(7):627-33.
  224. Hsing AW, Chen C, Chokkalingam AP, Gao YT, Dightman DA, Nguyen HT, Deng J, Cheng J, Sesterhenn IA, Mostofi FK, Stanczyk FZ, Reichardt JK. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiology, Biomarkers and Prevention 2001 Oct;10(10):1077-82.
  225. Hsu L, Prentice RL, Stanford JL. Some further results on incorporating risk factor information in assessing the dependence between paired failure times arising from case-control family studies: an application to prostate cancer. Statistics in Medicine 2002 Mar;21(6):863-76.
  226. Huang D, Liu X, Plymate SR, Idowu M, Grimes M, Best AM, McKinney JL, Ware JL. Proteomic identification of 14-3-3 sigma as a common component of the androgen receptor and the epidermal growth factor receptor signaling pathways of the human prostate epithelial cell line M12. Oncogene 2004 Sep;23(41):6881-9.
  227. Huizen IV, Wu G, Moussa M, Chin JL, Fenster A, Lacefield JC, Sakai H, Greenberg NM, Xuan JW. Establishment of a serum tumor marker for preclinical trials of mouse prostate cancer models. Clinical Cancer Research 2005 Nov;11(21):7911-9.
  228. Hurtado-Coll A, Goldenberg SL, Gleave ME, Klotz L. Intermittent androgen suppression in prostate cancer: the Canadian experience. Urology 2002 Sep;60(3 Suppl 1):52-6; discussion 56.
  229. Hurtado-coll A, Goldenberg SL, Klotz L, Gleave ME. Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the Canadian experience. Urology 2002 Sep;60(3 Suppl 1):45-51; discussion 51.
  230. Huss WJ, Barrios RJ, Foster BA, Greenberg NM. Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression. Prostate 2003 Jan;54(1):8-16.
  231. Huss WJ, Barrios RJ, Greenberg NM. SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis. Mol Cancer Ther 2003 Jul;2(7):611-6.
  232. Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Research 2005 Aug;65(15):6640-50.
  233. Huss WJ, Lai L, Barrios RJ, Hirschi KK, Greenberg NM. Retinoic acid slows progression and promotes apoptosis of spontaneous prostate cancer. Prostate 2004 Oct;61(2):142-52.
  234. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). Journal of Clinical Oncology 2006 Aug;24(24):3984-90.
  235. Hussain M, Tangen CM, Lara PN Jr, Vaishampayan UN, Petrylak DP, Colevas AD, Sakr WA, Crawford ED. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. Journal of Clinical Oncology 2005 Dec;23(34):8724-9.
  236. Hyytinen ER, Saadut R, Chen C, Paull L, Koivisto PA, Vessella RL, Frierson HF Jr, Dong JT. Defining the region(s) of deletion at 6q16-q22 in human prostate cancer. Genes, Chromosomes and Cancer 2002 Jul;34(3):306-12.
  237. Inoue LY, Etzioni R, Slate EH, Morrell C, Penson DF. Combining longitudinal studies of PSA. Biostatistics 2004 Jul;5(3):483-500.
  238. Jackson JK, Gleave ME, Gleave J, Burt HM. The inhibition of angiogenesis by antisense oligonucleotides to clusterin. Angiogenesis 2005;8(3):229-38.
  239. Janer M, Friedrichsen DM, Stanford JL, Badzioch MD, Kolb S, Deutsch K, Peters MA, Goode EL, Welti R, DeFrance HB, Iwasaki L, Li S, Hood L, Ostrander EA, Jarvik GP. Genomic scan of 254 hereditary prostate cancer families. Prostate 2003 Dec;57(4):309-19.
  240. Janoff DM, Peterson C, Mongoue-Tchokote S, Peters L, Beer TM, Wersinger EM, Mori M, Garzotto M. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer. BJU International 2005 Sep;96(4):503-7.
  241. Jin C, McKeehan K, Guo W, Jauma S, Ittmann MM, Foster B, Greenberg NM, McKeehan WL, Wang F. Cooperation between ectopic FGFR1 and depression of FGFR2 in induction of prostatic intraepithelial neoplasia in the mouse prostate. Cancer Research 2003 Dec;63(24):8784-90.
  242. Johnson TK, Gilliland FD, Hoffman RM, Deapen D, Penson DF, Stanford JL, Albertsen PC, Hamilton AS. Racial/Ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer. Journal of Clinical Oncology 2004 Oct;22(20):4193-201.
  243. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002 Feb;50(3):179-88.
  244. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA, Greenberg NM. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003 May;55(3):219-37.
  245. Kazansky AV, Spencer DM, Greenberg NM. Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system. Cancer Research 2003 Dec;63(24):8757-62.
  246. Kedishvili NY, Chumakova OV, Chetyrkin SV, Belyaeva OV, Lapshina EA, Lin DW, Matsumura M, Nelson PS. Evidence that the human gene for prostate short-chain dehydrogenase/reductase (PSDR1) encodes a novel retinal reductase (RalR1). Journal of Biological Chemistry 2002 Aug;277(32):28909-15.
  247. Khodavirdi AC, Song Z, Yang S, Zhong C, Wang S, Wu H, Pritchard C, Nelson PS, Roy-Burman P. Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Research 2006 Jan;66(2):883-8.
  248. Kiefer JA, Vessella RL, Quinn JE, Odman AM, Zhang J, Keller ET, Kostenuik PJ, Dunstan CR, Corey E. The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clinical and Experimental Metastasis 2004;21(5):381-7.
  249. Kim TS, Heinlein C, Hackman RC, Nelson PS. Phenotypic analysis of mice lacking the Tmprss2-encoded protease. Molecular and Cellular Biology 2006 Feb;26(3):965-75.
  250. King IB, Kristal AR, Schaffer S, Thornquist M, Goodman GE. Serum trans-fatty acids are associated with risk of prostate cancer in beta-Carotene and Retinol Efficacy Trial. Cancer Epidemiology, Biomarkers and Prevention 2005 Apr;14(4):988-92.
  251. Kirsh VA, Hayes RB, Mayne ST, Chatterjee N, Subar AF, Dixon LB, Albanes D, Andriole GL, Urban DA, Peters U. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. Journal of the National Cancer Institute 2006 Feb;98 (4):245-54.
  252. Kirsh VA, Mayne ST, Peters U, Chatterjee N, Leitzmann MF, Dixon LB, Urban DA, Crawford ED, Hayes RB. A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiology, Biomarkers and Prevention 2006 Jan;15(1):92-8.
  253. Kiyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D, Miyake H, Gleave ME. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Research 2003 Jul;63(13):3575-84.
  254. Kizu H, Takayama T, Fukuda M, Egawa M, Tsushima H, Yamada M, Ichiyanagi K, Yokoyama K, Onoguchi M, Tonami N. Fusion of SPECT and multidetector CT images for accurate localization of pelvic sentinel lymph nodes in prostate cancer patients. Journal of Nuclear Medicine Technology 2005 Jun;33(2):78-82.
  255. Klein CE, Tangen CM, Braun TJ, Hussain MH, Peereboom DM, Nichols CR, Rivkin SE, Dakhil SR, Crawford ED. SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group study. Prostate 2002 Sep;52(4):264-8.
  256. Klein EA, Tangen CM, Goodman PJ, Lippman SM, Thompson IM. Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited. Journal of Clinical Oncology 2005 Oct;23(30):7460-6.
  257. Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 2004 Aug;6(2):185-95.
  258. Knudsen BS, Edlund M. Prostate cancer and the met hepatocyte growth factor receptor. Advances in Cancer Research 2004;91:31-67.
  259. Knudsen BS, Gmyrek GA, Inra J, Scherr DS, Vaughan ED, Nanus DM, Kattan MW, Gerald WL, Vande Woude GF. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 2002 Dec;60(6):1113-7.
  260. Knudsen BS, Lucas JM, Fazli L, Hawley S, Falcon S, Coleman IM, Martin DB, Xu C, True LD, Gleave ME, Nelson PS, Ayala GE. Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate. American Journal of Pathology 2005 Jul;167(1):255-66.
  261. Knudsen BS, Miranti CK. The impact of cell adhesion changes on proliferation and survival during prostate cancer development and progression. Journal of Cellular Biochemistry 2006 Oct;99(2):345-61.
  262. Kojima S, Mulholland DJ, Ettinger S, Fazli L, Nelson CC, Gleave ME. Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer models. Prostate 2006 Jun;66(9):971-86.
  263. Koochekpour S, Zhuang YJ, Beroukhim R, Hsieh CL, Hofer MD, Zhau HE, Hiraiwa M, Pattan DY, Ware JL, Luftig RB, Sandhoff K, Sawyers CL, Pienta KJ, Rubin MA, Vessella RL, Sellers WR, Sartor O. Amplification and overexpression of prosaposin in prostate cancer. Genes, Chromosomes and Cancer 2005 Dec;44(4):351-64.
  264. Koralek DO, Peters U, Andriole G, Reding D, Kirsh V, Subar A, Schatzkin A, Hayes R, Leitzmann MF. A prospective study of dietary alpha-linolenic acid and the risk of prostate cancer (United States). Cancer Causes and Control 2006 Aug;17(6):783-91.
  265. Korenchuk S, Lehr JE, MClean L, Lee YG, Whitney S, Vessella R, Lin DL, Pienta KJ. VCaP, a cell-based model system of human prostate cancer. In Vivo 2001 Mar-2001 Apr;15(2):163-8.
  266. Koumakpayi IH, Diallo JS, Le Page C, Lessard L, Gleave M, Begin LR, Mes-Masson AM, Saad F. Expression and nuclear localization of ErbB3 in prostate cancer. Clinical Cancer Research 2006 May;12(9):2730-7.
  267. Kristal AR. Diet and trend in prostate-specific antigen: inferences for prostate cancer risk. Journal of Clinical Oncology 2002 Sep;20(17):3570-1.
  268. Kristal AR. Vitamin A, retinoids and carotenoids as chemopreventive agents for prostate cancer. Journal of Urology 2004 Feb;171(2 Pt 2):S54-8; discussion S58.
  269. Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer 2006 Jan;106(2):320-8.
  270. Kristal AR, Cohen JH, Qu P, Stanford JL. Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiology, Biomarkers and Prevention 2002 Aug;11(8):719-25.
  271. Kristal AR, King IB, Albanes D, Pollak MN, Stanzyk FZ, Santella RM, Hoque A. Centralized blood processing for the selenium and vitamin E cancer prevention trial: effects of delayed processing on carotenoids, tocopherols, insulin-like growth factor-I, insulin-like growth factor binding protein 3, steroid hormones, and lymphocyte viability. Cancer Epidemiology, Biomarkers and Prevention 2005 Mar;14(3):727-30.
  272. Kristal AR, Lampe JW. Brassica vegetables and prostate cancer risk: a review of the epidemiological evidence. Nutrition and Cancer 2002;42(1):1-9.
  273. Kristal AR, Schenk JM. Directions for future epidemiological research in lycopene and prostate cancer risk. Journal of Nutrition 2005 Aug;135(8):2037S-9S.
  274. Kristal AR, Stanford JL. Cruciferous vegetables and prostate cancer risk: confounding by PSA screening. Cancer Epidemiology, Biomarkers and Prevention 2004 Jul;13(7):1265.
  275. Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L, Gleave ME, Cox ME. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Research 2004 Dec;64(23):8620-9.
  276. Kurek R, Nunez G, Tselis N, Konrad L, Martin T, Roeddiger S, Aumuller G, Zamboglou N, Lin DW, Tunn UW, Renneberg H. Prognostic value of combined “triple”-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients. Clinical Cancer Research 2004 Sep;10(17):5808-14.
  277. Lahn M, Sundell K, Gleave M, Ladan F, Su C, Li S, Ma D, Paterson BM, Bumol TF. Protein kinase C-alpha in prostate cancer. BJU International 2004 May;93(7):1076-81.
  278. Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, Ho SM, Vessella RL, Corey E. Metastases of prostate cancer express estrogen receptor-beta. Urology 2004 Oct;64(4):814-20.
  279. Laitinen S, Karhu R, Sawyers CL, Vessella RL, Visakorpi T. Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization. Genes, Chromosomes and Cancer 2002 Sep;35(1):66-73.
  280. Lam JS, Yamashiro J, Shintaku IP, Vessella RL, Jenkins RB, Horvath S, Said JW, Reiter RE. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clinical Cancer Research 2005 Apr;11(7):2591-6.
  281. Lamharzi N, Johnson MM, Goodman G, Etzioni R, Weiss NS, Dightman DA, Barnett M, DiTommaso D, Chen C. Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer. International Journal of Cancer 2003 Jul;105(4):480-3.
  282. Landis D, Wallner K, Locke J, Ellis W, Russell K, Cavanagh W, Blasko J. Late urinary function after prostate brachytherapy. Brachytherapy 2002;1(1):21-6.
  283. Lange PH. PROSTASCINT scan for staging prostate cancer. Urology 2001 Mar;57(3):402-6.
  284. Lange PH. Investigations of androgen suppressive agents for prostate cancer–still pertinent, still exciting. Journal of Urology 2003 May;169(5):1745-6.
  285. Lange PH, Stanford JL. Pacific Northwest Prostate Cancer SPORE. Clin Adv Hematol Oncol 2004 Apr;2(4):245-7.
  286. Lavelle M, Schuff KG, Keller FS, Binkert CA, O’Hara M, Fairfax CA, Beer TM. Unilateral autonomous testicular testosterone production mimicking androgen independent prostate cancer. Journal of Urology 2002 Sep;168(3):1098-9.
  287. Le L, Chi K, Tyldesley S, Flibotte S, Diamond DL, Kuzyk MA, Sadar MD. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clinical Chemistry 2005 Apr;51(4):695-707.
  288. Lee EC, Frolov A, Li R, Ayala G, Greenberg NM. Targeting Aurora kinases for the treatment of prostate cancer. Cancer Research 2006 May;66(10):4996-5002.
  289. Lei Q, Jiao J, Xin L, Chang CJ, Wang S, Gao J, Gleave ME, Witte ON, Liu X, Wu H. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 2006 May;9(5):367-78.
  290. Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. British Journal of Cancer 2005 Oct;93(9):1019-23.
  291. Leung S, Miyake H, Zellweger T, Tolcher A, Gleave ME. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. International Journal of Cancer 2001 Mar;91(6):846-50.
  292. Li PE, Nelson PS. Prostate cancer genomics. Curr Urol Rep 2001 Feb;2(1):70-8.
  293. Lin B, White JT, Ferguson C, Wang S, Vessella R, Bumgarner R, True LD, Hood L, Nelson PS. Prostate short-chain dehydrogenase reductase 1 (PSDR1): a new member of the short-chain steroid dehydrogenase/reductase family highly expressed in normal and neoplastic prostate epithelium. Cancer Research 2001 Feb;61(4):1611-8.
  294. Lin B, White JT, Lu W, Xie T, Utleg AG, Yan X, Yi EC, Shannon P, Khrebtukova I, Lange PH, Goodlett DR, Zhou D, Vasicek TJ, Hood L. Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease. Cancer Research 2005 Apr;65(8):3081-91.
  295. Lin B, White JT, Utleg AG, Wang S, Ferguson C, True LD, Vessella R, Hood L, Nelson PS. Isolation and characterization of human and mouse WDR19,a novel WD-repeat protein exhibiting androgen-regulated expression in prostate epithelium. Genomics 2003 Sep;82(3):331-42.
  296. Lin DW, Coleman IM, Hawley S, Dumpit R, Gifford D, Kezele P, Hung H, Knudsen BS, Kristal AR, Nelson PS. Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis. Journal of Clinical Oncology 2006 Aug;24(23):3763-70.
  297. Lin DW, Nelson PS. The role of cyclooxygenase-2 inhibition for the prevention and treatment of prostate carcinoma. Clin Prostate Cancer 2003 Sep;2(2):119-26.
  298. Linja MJ, Porkka KP, Kang Z, Savinainen KJ, Janne OA, Tammela TL, Vessella RL, Palvimo JJ, Visakorpi T. Expression of androgen receptor coregulators in prostate cancer. Clinical Cancer Research 2004 Feb;10(3):1032-40.
  299. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Research 2001 May;61(9):3550-5.
  300. Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM Jr, Kristal AR, Santella RM, Probstfield JL, Moinpour CM, Albanes D, Taylor PR, Minasian LM, Hoque A, Thomas SM, Crowley JJ, Gaziano JM, Stanford JL, Cook ED, Fleshner NE, Lieber MM, Walther PJ, Khuri FR, Karp DD, Schwartz GG, Ford LG, Coltman CA Jr. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute 2005 Jan;97(2):94-102.
  301. Littman AJ, Kristal AR, White E. Recreational physical activity and prostate cancer risk (United States). Cancer Causes and Control 2006 Aug;17(6):831-41.
  302. Liu AY, Brubaker KD, Goo YA, Quinn JE, Kral S, Sorensen CM, Vessella RL, Belldegrun AS, Hood LE. Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines. Prostate 2004 Jul;60(2):98-108.
  303. Liu AY, Nelson PS, van den Engh G, Hood L. Human prostate epithelial cell-type cDNA libraries and prostate expression patterns. Prostate 2002 Feb;50(2):92-103.
  304. Liu AY, Peehl DM. Characterization of cultured human prostatic epithelial cells by cluster designation antigen expression. Cell and Tissue Research 2001 Sep;305(3):389-97.
  305. Liu AY, Roudier MP, True LD. Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. American Journal of Pathology 2004 Nov;165(5):1543-56.
  306. Liu AY, True LD. Characterization of prostate cell types by CD cell surface molecules. American Journal of Pathology 2002 Jan;160(1):37-43.
  307. Liu AY, Zhang H, Sorensen CM, Diamond DL. Analysis of prostate cancer by proteomics using tissue specimens. Journal of Urology 2005 Jan;173(1):73-8.
  308. Liu C, Huang H, Donate F, Dickinson C, Santucci R, El-Sheikh A, Vessella R, Edgington TS. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Research 2002 Oct;62(19):5470-5.
  309. Lu W, Zhou D, Glusman G, Utleg AG, White JT, Nelson PS, Vasicek TJ, Hood L, Lin B. KLK31P is a novel androgen regulated and transcribed pseudogene of kallikreins that is expressed at lower levels in prostate cancer cells than in normal prostate cells. Prostate 2006 Jun;66(9):936-44.
  310. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002 Oct;325(7367):740.
  311. Lubieniecka JM, Cheteri MK, Stanford JL, Ostrander EA. Met160Val polymorphism in the TMPRSS2 gene and risk of prostate cancer in a population-based case-control study. Prostate 2004 Jun;59(4):357-9.
  312. Maddison LA, Huss WJ, Barrios RM, Greenberg NM. Differential expression of cell cycle regulatory molecules and evidence for a “cyclin switch” during progression of prostate cancer. Prostate 2004 Mar;58(4):335-44.
  313. Maddison LA, Sutherland BW, Barrios RJ, Greenberg NM. Conditional deletion of Rb causes early stage prostate cancer. Cancer Research 2004 Sep;64(17):6018-25.
  314. Majeed N, Blouin MJ, Kaplan-Lefko PJ, Barry-Shaw J, Greenberg NM, Gaudreau P, Bismar TA, Pollak M. A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene 2005 Jul;24(29):4736-40.
  315. Maki HE, Waltering KK, Wallen MJ, Martikainen PM, Tammela TL, van Weerden WM, Vessella RL, Visakorpi T. Screening of genetic and expression alterations of SRC1 gene in prostate cancer. Prostate 2006 Sep;66(13):1391-8.
  316. Man A, Pickles T, Chi KN. Asian race and impact on outcomes after radical radiotherapy for localized prostate cancer. Journal of Urology 2003 Sep;170(3):901-4.
  317. Marshall JR, Sakr W, Wood D, Berry D, Tangen C, Parker F, Thompson I, Lippman SM, Lieberman R, Alberts D, Jarrard D, Coltman C, Greenwald P, Minasian L, Crawford ED. Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia. Cancer Epidemiology, Biomarkers and Prevention 2006 Aug;15(8):1479-84.
  318. Martin DB, Gifford DR, Wright ME, Keller A, Yi E, Goodlett DR, Aebersold R, Nelson PS. Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Research 2004 Jan;64(1):347-55.
  319. Matsumura M, Bhatt AS, Andress D, Clegg N, Takayama TK, Craik CS, Nelson PS. Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries. Prostate 2005 Jan;62(1):1-13.
  320. McNeel DG, Nguyen LD, Ellis WJ, Higano CS, Lange PH, Disis ML. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. Prostate 2001 May;47(3):222-9.
  321. Melchior SW, Noteboom J, Gillitzer R, Lange PH, Blumenstein BA, Vessella RL. The percentage of free prostate-specific antigen does not predict extracapsular disease in patients with clinically localized prostate cancer before radical prostatectomy. BJU International 2001 Aug;88(3):221-5.
  322. Mentor-Marcel R, Lamartiniere CA, Eltoum IA, Greenberg NM, Elgavish A. Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP). Journal of Nutrition 2005 May;135(5):989-95.
  323. Merrick GS, Butler WM, Wallner KE. Comparison of MRI pulse sequences in defining prostate volume after permanent implantation: in regard to McLaughlin et al., IJROBP 2002;54:703-711. International Journal of Radiation Oncology, Biology, Physics 2003 Jul;56(3):906; author reply 906-7.
  324. Merrick GS, Butler WM, Wallner KE, Allen Z, DeFilippo JL, Adamovich E. Enzymatic prostatic acid phosphatase in the clinical staging of patients diagnosed with prostate cancer. West Virginia Medical Journal 2005 May-2005 Jun;101(3):116-9.
  325. Merrick GS, Butler WM, Wallner KE, Allen Z, Galbreath RW, Lief JH. Brachytherapy-related dysuria. BJU International 2005 Mar;95(4):597-602.
  326. Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW, Lief JH, Reed DJ. The impact of radiation dose to the urethra on brachytherapy-related dysuria. Brachytherapy 2005;4(1):45-50.
  327. Merrick GS, Butler WM, Wallner KE, Allen ZA, Lief JH, Hinerman-Mulroy A, Galbreath RW. The impact of prostate volume and neoadjuvant androgen-deprivation therapy on urinary function following prostate brachytherapy. Cancer J 2004 May-2004 Jun;10(3):181-9.
  328. Merrick GS, Butler WM, Wallner KE, Blasko JC, Michalski J, Aronowitz J, Grimm P, Moran BJ, McLaughlin PW, Usher J, Lief JH, Allen ZA. Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis. Brachytherapy 2005;4(4):241-51.
  329. Merrick GS, Butler WM, Wallner KE, Burden LR, Dougherty JE. Extracapsular radiation dose distribution after permanent prostate brachytherapy. American Journal of Clinical Oncology 2003 Oct;26(5):e178-89.
  330. Merrick GS, Butler WM, Wallner KE, Galbreath RW. Effect of transurethral resection on urinary quality of life after permanent prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics 2004 Jan;58(1):81-8.
  331. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Adamovich E. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. Urology 2004 Oct;64(4):754-9.
  332. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Adamovich E. Permanent interstitial brachytherapy for clinically organ-confined high-grade prostate cancer with a pretreatment PSA < 20 ng/mL. American Journal of Clinical Oncology 2004 Dec;27(6):611-5.
  333. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Adamovich E. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer. West Virginia Medical Journal 2005 Jul-2005 Aug;101(4):168-71.
  334. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen Z, Adamovich E. Temporal effect of neoadjuvant androgen deprivation therapy on PSA kinetics following permanent prostate brachytherapy with or without supplemental external beam radiation. Brachytherapy 2004;3(3):141-6.
  335. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen Z, Lief JH, Adamovich E. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. Urology 2005 Jan;65(1):95-100.
  336. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E. The impact of primary Gleason grade on biochemical outcome following brachytherapy for hormone-naive Gleason score 7 prostate cancer. Cancer J 2005 May-2005 Jun;11(3):234-40.
  337. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E. Prognostic significance of perineural invasion on biochemical progression-free survival after prostate brachytherapy. Urology 2005 Nov;66(5):1048-53.
  338. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics 2006 Jul;65(3):669-77.
  339. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Kurko B. Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy. Urology 2006 Jul;68(1):116-20.
  340. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL. Prostate-specific antigen spikes after permanent prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics 2002 Oct;54(2):450-6.
  341. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL, Allen ZA, Adamovich E. Risk factors for the development of prostate brachytherapy related urethral strictures. Journal of Urology 2006 Apr;175(4):1376-80; discussion 1381.
  342. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL, Kurko BS, Lief JH, Allen ZA. Erectile function after prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics 2005 Jun;62(2):437-47.
  343. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Kurko B, Cleavinger S. Rectal function following brachytherapy with or without supplemental external beam radiation: results of two prospective randomized trials. Brachytherapy 2003;2(3):147-57.
  344. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH. Long-term urinary quality of life after permanent prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics 2003 Jun;56(2):454-61.
  345. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Adamovich E. Prognostic significance of percent positive biopsies in clinically organ-confined prostate cancer treated with permanent prostate brachytherapy with or without supplemental external-beam radiation. Cancer J 2004 Jan-2004 Feb;10(1):54-60.
  346. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Adamovich E. Effect of cigarette smoking on biochemical outcome after permanent prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics 2004 Mar;58(4):1056-62.
  347. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Allen Z, Adamovich E. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics 2005 Jan;61(1):32-43.
  348. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Murray B, Zeroski D, Lief JH. Dysuria after permanent prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics 2003 Mar;55(4):979-85.
  349. Merrick GS, Butler WM, Wallner KE, Hines AL, Allen Z. Late rectal function after prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics 2003 Sep;57(1):42-8.
  350. Merrick GS, Butler WM, Wallner KE, Lief JH, Anderson RL, Smeiles BJ, Galbreath RW, Benson ML. The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction. International Journal of Radiation Oncology, Biology, Physics 2002 Nov;54(4):1055-62.
  351. Merrick GS, Butler WM, Wallner KE, Lief JH, Galbreath RW. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology 2002 Oct;60(4):650-5.
  352. Merrick GS, Butler WM, Wallner KE, Lief JH, Hinerman-Mulroy A, Galbreath RW. Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy. Brachytherapy 2003;2(3):181-8.
  353. Merrick GS, Butler WM, Wallner KE, Murray B, Allen Z, Lief JH, Galbreath RW. The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy. Brachytherapy 2004;3(1):22-9.
  354. Merrick GS, Butler WM, Wallner KE, Murray BC, Allen Z, Galbreath RW. Influence of hormonal therapy on late rectal function after permanent prostate brachytherapy with or without supplemental external beam radiotherapy. International Journal of Radiation Oncology, Biology, Physics 2004 Jan;58(1):68-74.
  355. Merrick GS, Wallner KE, Butler WM. Management of sexual dysfunction after prostate brachytherapy. Oncology (Williston Park) 2003 Jan;17(1):52-62; discussion 62, 67-70, 73.
  356. Merrick GS, Wallner KE, Butler WM. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. Journal of Urology 2003 May;169(5):1643-52.
  357. Merrick GS, Wallner KE, Butler WM. Minimizing prostate brachytherapy-related morbidity. Urology 2003 Nov;62(5):786-92.
  358. Merrick GS, Wallner KE, Butler WM. Patient selection for prostate brachytherapy: more myth than fact. Oncology (Williston Park) 2004 Apr;18(4):445-52; discussion 452, 455-7.
  359. Merrick GS, Wallner KE, Butler WM. Morbidity after brachytherapy for prostate adenocarcinoma. Mayo Clinic Proceedings 2004 Jul;79(7):945-6; author reply 947-9.
  360. Merrick GS, Wallner KE, Butler WM. Prostate cryotherapy: more questions than answers. Urology 2005 Jul;66(1):9-15.
  361. Merrick GS, Wallner KE, Butler WM, Blasko JC. Permanent prostate brachytherapy: is supplemental external-beam radiation therapy necessary? Oncology (Williston Park) 2006 Apr;20(5):514-22; discussion 522-5.
  362. Merrick GS, Wallner KE, Butler WM, Galbreath RW, Allen ZA, Adamovich E, True L. Brachytherapy in men aged < or = 54 years with clinically localized prostate cancer. BJU International 2006 Aug;98(2):324-8.
  363. Michels J, Chi KN. Hormonal therapy for prostate cancer: can bicalutamide-induced gynecomastia and breast pain be prevented? Nat Clin Pract Urol 2006 Apr;3(4):186-7.
  364. Miller EA, Stanford JL, Hsu L, Noonan E, Ostrander EA. Polymorphic repeats in the androgen receptor gene in high-risk sibships. Prostate 2001 Aug;48(3):200-5.
  365. Miyake H, Hara I, Fujisawa M, Gleave ME. The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer. Expert Opin Investig Drugs 2006 May;15(5):507-17.
  366. Miyake H, Hara I, Gleave ME. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic. International Journal of Urology 2005 Sep;12(9):785-94.
  367. Miyake H, Hara I, Gleave ME, Eto H. Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen. Prostate 2004 Dec;61(4):318-23.
  368. Miyake H, Hara I, Kamidono S, Gleave ME. Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity. International Journal of Urology 2001 Jul;8(7):337-49.
  369. Miyake H, Hara I, Kamidono S, Gleave ME, Eto H. Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression. Oncology Reports 2003 Mar-2003 Apr;10(2):469-73.
  370. Miyake H, Yamanaka K, Muramaki M, Kurahashi T, Gleave M, Hara I. Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer. Oncology Reports 2005 Nov;14(5):1371-5.
  371. Montgomery BS, Borwell JP, Higgins DM. Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection. Prostate Cancer Prostatic Dis 2005;8(1):66-8.
  372. Montgomery RB, Bonham M, Nelson PS, Grim J, Makary E, Vessella R, Stahl WL. Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells. Prostate 2005 Oct;65(2):141-50.
  373. Moore S, Knudsen B, True LD, Hawley S, Etzioni R, Wade C, Gifford D, Coleman I, Nelson PS. Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma. International Journal of Cancer 2005 Apr;114(4):563-71.
  374. Moore S, Pritchard C, Lin B, Ferguson C, Nelson PS. Isolation and characterization of the murine prostate short-chain dehydrogenase/reductase 1 (Psdr1) gene, a new member of the short-chain steroid dehydrogenase/reductase family. Gene 2002 Jun;293(1-2):149-60.
  375. Moore SM, Nelson PS. Gene expression profiling of the human prostate androgen response program. Journal of Andrology 2002 Mar-2002 Apr;23(2):163-9.
  376. Mouraviev V, Gleave ME. A meaningful legacy: urologists as Nobel Prize laureates. Can J Urol 2003 Feb;10(1):1737-42.
  377. Moyad MA, Merrick GS, Butler WM, Wallner KE, Galbreath RW, Butler EG, Allen ZA, Adamovich E. Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer. Urologic Nursing 2006 Aug;26(4):298-303.
  378. Moyad MA, Merrick GS, Butler WM, Wallner KE, Galbreath RW, Kurko B, Adamovich E. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 2005 Dec;66(6):1150-4.
  379. Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC. The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. Journal of Biological Chemistry 2002 May;277(20):17933-43.
  380. Mulholland DJ, Cox M, Read J, Rennie P, Nelson C. Androgen responsiveness of Renilla luciferase reporter vectors is promoter, transgene, and cell line dependent. Prostate 2004 May;59(2):115-9.
  381. Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocrine Reviews 2005 Dec;26(7):898-915.
  382. Mulholland DJ, Dedhar S, Wu H, Nelson CC. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene 2006 Jan;25(3):329-37.
  383. Mulholland DJ, Read JT, Rennie PS, Cox ME, Nelson CC. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis. Oncogene 2003 Aug;22(36):5602-13.
  384. Nagata M, Sato T, Un-no T, Nagae H, Mugiya S, Takayama T, Suzuki K, Fujita K. [Repeat prostate biopsy in patients with previous negative biopsies]. Hinyokika Kiyo. Acta Urologica Japonica 2002 Oct;48(10):589-92.
  385. Nanda NK, Birch L, Greenberg NM, Prins GS. MHC class I and class II molecules are expressed in both human and mouse prostate tumor microenvironment. Prostate 2006 Sep;66(12):1275-84.
  386. Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E, Katz A, Isaacs WB, Hebbring S, Komiya A, McDonnell SK, Wiley KE, Jacobsen SJ, Isaacs SD, Walsh PC, Zheng SL, Chang BL, Friedrichsen DM, Stanford JL, Ostrander EA, Chinnaiyan AM, Rubin MA, Xu J, Thibodeau SN, Friedman SL, Martignetti JA. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Research 2005 Feb;65(4):1213-22.
  387. Nelson CC, Hoffart D, Gleave ME, Rennie PS. Application of gene microarrays in the study of prostate cancer. Methods Mol Med 2003;81:299-320.
  388. Nelson PS. Identifying immunotherapeutic targets for prostate carcinoma through the analysis of gene expression profiles. Annals of the New York Academy of Sciences 2002 Dec;975:232-46.
  389. Nelson PS. Predicting prostate cancer behavior using transcript profiles. Journal of Urology 2004 Nov;172(5 Pt 2):S28-32; discussion S33.
  390. Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, Hood L, Lin B. The program of androgen-responsive genes in neoplastic prostate epithelium. Proceedings of the National Academy of Sciences of the United States of America 2002 Sep;99(18):11890-5.
  391. Nelson PS, Montgomery B. Unconventional therapy for prostate cancer: good, bad or questionable? Nat Rev Cancer 2003 Nov;3(11):845-58.
  392. Nelson PS, Montgomery B. Cell type-specific analyses for identifying prostate cancer biomarkers. Curr Urol Rep 2006 Jan;7(1):57-63.
  393. Nelson PS, Pritchard C, Abbott D, Clegg N. The human (PEDB) and mouse (mPEDB) Prostate Expression Databases. Nucleic Acids Res 2002 Jan;30(1):218-20.
  394. Nelson PS, Stanford JL, Ostrander EA. Prostate cancer research in the post-genome era. Epidemiologic Reviews 2001;23(1):187-90.
  395. Neuhouser ML, Kristal AR, Patterson RE, Goodman PJ, Thompson IM. Dietary supplement use in the Prostate Cancer Prevention Trial: implications for prevention trials. Nutrition and Cancer 2001;39(1):12-8.
  396. Newcomer LM, King IB, Wicklund KG, Stanford JL. The association of fatty acids with prostate cancer risk. Prostate 2001 Jun;47(4):262-8.
  397. Nickel JC, True LD, Krieger JN, Berger RE, Boag AH, Young ID. Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU International 2001 Jun;87(9):797-805.
  398. Niehaus A, Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW, Adamovich E. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy. International Journal of Radiation Oncology, Biology, Physics 2006 Jan;64(1):136-43.
  399. Nupponen NN, Wallen MJ, Ponciano D, Robbins CM, Tammela TL, Vessella RL, Carpten JD, Visakorpi T. Mutational analysis of susceptibility genes RNASEL/HPC1, ELAC2/HPC2, and MSR1 in sporadic prostate cancer. Genes, Chromosomes and Cancer 2004 Feb;39(2):119-25.
  400. Okihara K, Cheli CD, Partin AW, Fritche HA, Chan DW, Sokoll LJ, Brawer MK, Schwartz MK, Vessella RL, Loughlin KR, Johnston DA, Babaian RJ. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. Journal of Urology 2002 May;167(5):2017-23; discussion 2023-4.
  401. Ostrander EA, Markianos K, Stanford JL. Finding prostate cancer susceptibility genes. Annu Rev Genomics Hum Genet 2004;5:151-75.
  402. Oudes AJ, Campbell DS, Sorensen CM, Walashek LS, True LD, Liu AY. Transcriptomes of human prostate cells. BMC Genomics 2006;7:92.
  403. Oudes AJ, Roach JC, Walashek LS, Eichner LJ, True LD, Vessella RL, Liu AY. Application of Affymetrix array and Massively Parallel Signature Sequencing for identification of genes involved in prostate cancer progression. BMC Cancer 2005;5:86.
  404. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. Journal of Clinical Endocrinology and Metabolism 2005 Mar;90(3):1502-10.
  405. Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, Nelson PS, Matsumoto AM, Bremner WJ. Persistent intraprostatic androgen concentrations after medical castration in healthy men. Journal of Clinical Endocrinology and Metabolism 2006 Oct;91(10):3850-6
  406. Panagiotou I, Beer TM, Hsieh YC, Mori M, Peters L, Klein T, Garzotto M. Predictors of delayed therapy after expectant management for localized prostate cancer in the era of prostate-specific antigen. Oncology 2004;67(3-4):194-202.
  407. Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL. Determining cause of death in prostate cancer: are death certificates valid? Journal of the National Cancer Institute 2001 Dec;93(23):1822-3.
  408. Penson DF, Feng Z, Kuniyuki A, McClerran D, Albertsen PC, Deapen D, Gilliland F, Hoffman R, Stephenson RA, Potosky AL, Stanford JL. General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. Journal of Clinical Oncology 2003 Mar;21(6):1147-54.
  409. Penson DF, McLerran D, Feng Z, Li L, Albertsen PC, Gilliland FD, Hamilton A, Hoffman RM, Stephenson RA, Potosky AL, Stanford JL. 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. Journal of Urology 2005 May;173(5):1701-5.
  410. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, Kuefer R, Vessella R, Sun XW, Meyerson M, Lee C, Sellers WR, Chinnaiyan AM, Rubin MA. TMPRSS2:ERG Fusion-Associated Deletions Provide Insight into the Heterogeneity of Prostate Cancer. Cancer Research 2006 Sep;66(17):8337-41.
  411. Peters MA, Janer M, Kolb S, Jarvik GP, Ostrander EA, Stanford JL. Germline mutations in the p73 gene do not predispose to familial prostate-brain cancer. Prostate 2001 Sep;48(4):292-6.
  412. Peters MA, Jarvik GP, Janer M, Chakrabarti L, Kolb S, Goode EL, Gibbs M, DuBois CC, Schuster EF, Hood L, Ostrander EA, Stanford JL. Genetic linkage analysis of prostate cancer families to Xq27-28. Human Heredity 2001;51(1-2):107-13.
  413. Peters ME, Ostrander EA. Prostate cancer: simplicity to complexity. Nature Genetics 2001 Feb;27(2):134-5.
  414. Pether M, Goldenberg SL, Bhagirath K, Gleave M. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience. Can J Urol 2003 Apr;10(2):1809-14.
  415. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. Journal of the National Cancer Institute 2006 Apr;98(8):516-21.
  416. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New England Journal of Medicine 2004 Oct;351(15):1513-20.
  417. Pfitzenmaier J, Ellis WJ, Arfman EW, Hawley S, McLaughlin PO, Lange PH, Vessella RL. Telomerase activity in disseminated prostate cancer cells. BJU International 2006 Jun;97(6):1309-13.
  418. Pfitzenmaier J, Quinn JE, Odman AM, Zhang J, Keller ET, Vessella RL, Corey E. Characterization of C4-2 prostate cancer bone metastases and their response to castration. Journal of Bone and Mineral Research 2003 Oct;18(10):1882-8.
  419. Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D Jr, Corey E. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 2003 Mar;97(5):1211-6.
  420. Plaskon LA, Penson DF, Vaughan TL, Stanford JL. Cigarette smoking and risk of prostate cancer in middle-aged men. Cancer Epidemiology, Biomarkers and Prevention 2003 Jul;12(7):604-9.
  421. Plymate SR, Haugk KH, Sprenger CC, Nelson PS, Tennant MK, Zhang Y, Oberley LW, Zhong W, Drivdahl R, Oberley TD. Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1. Oncogene 2003 Feb;22(7):1024-34.
  422. Plymate SR, Tennant MK, Culp SH, Woodke L, Marcelli M, Colman I, Nelson PS, Carroll JM, Roberts CT Jr, Ware JL. Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors. Prostate 2004 Nov;61(3):276-90.
  423. Polnaszek N, Kwabi-Addo B, Peterson LE, Ozen M, Greenberg NM, Ortega S, Basilico C, Ittmann M. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Research 2003 Sep;63(18):5754-60.
  424. Porkka KP, Nupponen NN, Tammela TL, Vessella RL, Visakorpi T. Human pHyde is not a classical tumor suppressor gene in prostate cancer. International Journal of Cancer 2003 Sep;106(5):729-35.
  425. Porkka KP, Tammela TL, Vessella RL, Visakorpi T. RAD21 and KIAA0196 at 8q24 are amplified and overexpressed in prostate cancer. Genes, Chromosomes and Cancer 2004 Jan;39(1):1-10.
  426. Porter MP, Stanford JL. Obesity and the risk of prostate cancer. Prostate 2005 Mar;62(4):316-21.
  427. Porter MP, Stanford JL, Lange PH. The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening. Prostate 2006 Jul;66(10):1044-51.
  428. Posadas EM, Gulley J, Arlen PM, Trout A, Parnes HL, Wright J, Lee MJ, Chung EJ, Trepel JB, Sparreboom A, Chen C, Jones E, Steinberg SM, Daniels A, Figg WD, Dahut WL. A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther 2005 Oct;4(10):1133-7.
  429. Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, Harlan LC. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. Journal of the National Cancer Institute 2004 Sep;96(18):1358-67.
  430. Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, Gilliland FD, Eley JW, Stephenson RA, Hoffman RM. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. Journal of Clinical Oncology 2001 Sep;19(17):3750-7.
  431. Potosky AL, Reeve BB, Clegg LX, Hoffman RM, Stephenson RA, Albertsen PC, Gilliland FD, Stanford JL. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. Journal of the National Cancer Institute 2002 Mar;94(6):430-7.
  432. Powell IJ, Tangen CM, Miller GJ, Lowe BA, Haas G, Carroll PR, Osswald MB, DeVere White R, Thompson IM Jr, Crawford ED. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109. Journal of Urology 2002 Nov;168(5):2016-9.
  433. Purnell JQ, Bland LB, Garzotto M, Lemmon D, Wersinger EM, Ryan CW, Brunzell JD, Beer TM. Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer. Journal of Lipid Research 2006 Feb;47(2):349-55.
  434. Qu Y, Adam BL, Thornquist M, Potter JD, Thompson ML, Yasui Y, Davis J, Schellhammer PF, Cazares L, Clements M, Wright GL Jr, Feng Z. Data reduction using a discrete wavelet transform in discriminant analysis of very high dimensionality data. Biometrics 2003 Mar;59(1):143-51.
  435. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, Feng Z, Semmes OJ, Wright GL Jr. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clinical Chemistry 2002 Oct;48(10):1835-43.
  436. Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate Cancer Prostatic Dis 2005;8(3):253-9.
  437. Rae LJ, Lober WB, Wolpin SE, Dockrey MR, Ellis WJ, Berry DL. Acceptability of an Internet treatment decision support program for men with prostate cancer. AMIA Annu Symp Proc 2005;1091.
  438. Rago RP, Einstein A Jr, Lush R, Beer TM, Ko YJ, Henner WD, Bubley G, Merica EA, Garg V, Ette E, Harding MW, Dalton WS. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemotherapy and Pharmacology 2003 Apr;51(4):297-305.
  439. Ralph JL, Orgebin-Crist MC, Lareyre JJ, Nelson CC. Disruption of androgen regulation in the prostate by the environmental contaminant hexachlorobenzene. Environmental Health Perspectives 2003 Apr;111(4):461-6.
  440. Rao MA, Cheng H, Quayle AN, Nishitani H, Nelson CC, Rennie PS. RanBPM, a nuclear protein that interacts with and regulates transcriptional activity of androgen receptor and glucocorticoid receptor. Journal of Biological Chemistry 2002 Dec;277(50):48020-7.
  441. Ray MR, Wafa LA, Cheng H, Snoek R, Fazli L, Gleave M, Rennie PS. Cyclin G-associated kinase: a novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer. International Journal of Cancer 2006 Mar;118(5):1108-19.
  442. Reed DR, Wallner KE, Merrick G, Butler W, Han BH, Sutlief SG, Cho PS. Isodose patterns in patients with inadequate prostate brachytherapy coverage. International Journal of Radiation Oncology, Biology, Physics 2003 Aug;56(5):1480-7.
  443. Reed DR, Wallner KE, Narayanan S, Sutlief SG, Ford EC, Cho PS. Intraoperative fluoroscopic dose assessment in prostate brachytherapy patients. International Journal of Radiation Oncology, Biology, Physics 2005 Sep;63(1):301-7.
  444. Reid KJ, Hendy SC, Saito J, Sorensen P, Nelson CC. Two classes of androgen receptor elements mediate cooperativity through allosteric interactions. Journal of Biological Chemistry 2001 Jan;276(4):2943-52.
  445. Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C, Gleave M. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Research 2005 Dec;65(23):11083-93.
  446. Rocchi P, Jugpal P, So A, Sinneman S, Ettinger S, Fazli L, Nelson C, Gleave M. Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro. BJU International 2006 Nov;98(5):1082-9
  447. Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Research 2004 Sep;64(18):6595-602.
  448. Rosenblatt KA, Carter JJ, Iwasaki LM, Galloway DA, Stanford JL. Serologic evidence of human papillomavirus 16 and 18 infections and risk of prostate cancer. Cancer Epidemiology, Biomarkers and Prevention 2003 Aug;12(8):763-8.
  449. Rosenblatt KA, Wicklund KG, Stanford JL. Sexual factors and the risk of prostate cancer. American Journal of Epidemiology 2001 Jun;153(12):1152-8.
  450. Rothman I, Stanford JL, Kuniyuki A, Berger RE. Self-report of prostatitis and its risk factors in a random sample of middle-aged men. Urology 2004 Nov;64(5):876-9; discussion 879-80.
  451. Roudier MP, Corey E, True LD, Hiagno CS, Ott SM, Vessell RL. Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases. Cancer Treatment and Research 2004;118:311-39.
  452. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, Vessella RL. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Human Pathology 2003 Jul;34(7):646-53.
  453. Roudier MP, True LD, Vessella RL, Higano CS. Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity. Journal of Clinical Pathology 2004 Mar;57(3):321-3.
  454. Roudier MP, Vesselle H, True LD, Higano CS, Ott SM, King SH, Vessella RL. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clinical and Experimental Metastasis 2003;20(2):171-80.
  455. Roy-Burman P, Tindall DJ, Robins DM, Greenberg NM, Hendrix MJ, Mohla S, Getzenberg RH, Isaacs JT, Pienta KJ. Androgens and prostate cancer: are the descriptors valid? Cancer Biol Ther 2005 Jan;4(1):4-5.
  456. Rubinstein M, Idelman G, Plymate SR, Narla G, Friedman SL, Werner H. Transcriptional activation of the insulin-like growth factor I receptor gene by the Kruppel-like factor 6 (KLF6) tumor suppressor protein: potential interactions between KLF6 and p53. Endocrinology 2004 Aug;145(8):3769-77.
  457. Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. Journal of Urology 2006 Sep;176(3):972-8; discussion 978.
  458. Saad F, Chi K, Fleshner N. The role of bisphosphonates in the management of bone metastases in prostate cancer. Can J Urol 2004 Oct;11(5):2376-82.
  459. Saad F, Finelli A, Dranitsaris G, Goldenberg L, Bagnell S, Gleave M, Fleshner N. Does prolonging the time to prostate cancer surgery impact long-term cancer control: a systematic review of the literature. Can J Urol 2006 Jun;13 Suppl 3:16-24.
  460. Saad F, Higano CS, Sartor O, Colombel M, Murray R, Mason MD, Tubaro A, Schulman C. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. Clin Genitourin Cancer 2006 Mar;4(4):257-62.
  461. Sabichi AL, Lee JJ, Taylor RJ, Thompson IM, Miles BJ, Tangen CM, Minasian LM, Pisters LL, Caton JR, Basler JW, Lerner SP, Menter DG, Marshall JR, Crawford ED, Lippman SM. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clinical Cancer Research 2006 Apr;12(7 Pt 1):2178-84.
  462. Salinas CA, Austin MA, Ostrander EO, Stanford JL. Polymorphisms in the androgen receptor and the prostate-specific antigen genes and prostate cancer risk. Prostate 2005 Sep;65(1):58-65.
  463. Saramaki OR, Porkka KP, Vessella RL, Visakorpi T. Genetic aberrations in prostate cancer by microarray analysis. International Journal of Cancer 2006 Sep;119(6):1322-9.
  464. Saramaki OR, Tammela TL, Martikainen PM, Vessella RL, Visakorpi T. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes, Chromosomes and Cancer 2006 Jul;45(7):639-45.
  465. Satia-Abouta J, Patterson RE, Schiller RN, Kristal AR. Energy from fat is associated with obesity in U.S. men: results from the Prostate Cancer Prevention Trial. Preventive Medicine 2002 May;34(5):493-501.
  466. Scher HI, Eisenberger M, D’Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. Journal of Clinical Oncology 2004 Feb;22(3):537-56.
  467. Schmittgen TD, Teske S, Vessella RL, True LD, Zakrajsek BA. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. International Journal of Cancer 2003 Nov;107(2):323-9.
  468. Schoonen WM, Salinas CA, Kiemeney LA, Stanford JL. Alcohol consumption and risk of prostate cancer in middle-aged men. International Journal of Cancer 2005 Jan;113(1):133-40.
  469. Schuster JM, Longo M, Nelson PS. Differential expression of bikunin (HAI-2/PB), a proposed mediator of glioma invasion, by demethylation treatment. Journal of Neuro-Oncology 2003 Sep;64(3):219-25.
  470. Seethammagari MR, Xie X, Greenberg NM, Spencer DM. EZC-prostate models offer high sensitivity and specificity for noninvasive imaging of prostate cancer progression and androgen receptor action. Cancer Research 2006 Jun;66(12):6199-209.
  471. Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clinical Chemistry 2005 Jan;51(1):102-12.
  472. Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A, Farris PE. Statins and prostate cancer risk: a case-control study. American Journal of Epidemiology 2005 Aug;162(4):318-25.
  473. Shariat SF, Roudier MP, Wilcox GE, Kattan MW, Scardino PT, Vessella RL, Erdamar S, Nguyen C, Wheeler TM, Slawin KM. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Research 2003 Aug;63(15):4662-70.
  474. Shaw PA, Etzioni R, Zeliadt SB, Mariotto A, Karnofski K, Penson DF, Weiss NS, Feuer EJ. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. American Journal of Epidemiology 2004 Dec;160(11):1059-69.
  475. Sherertz T, Wallner K, Wang H, Sutlief S, Russell K. Long-term urinary function after transperineal brachytherapy for patients with large prostate glands. International Journal of Radiation Oncology, Biology, Physics 2001 Dec;51(5):1241-5.
  476. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Archives of Internal Medicine 2006 Aug;166(15):1660-5.
  477. Shores MM, Sloan KL, Matsumoto AM, Moceri VM, Felker B, Kivlahan DR. Increased incidence of diagnosed depressive illness in hypogonadal older men. Archives of General Psychiatry 2004 Feb;61(2):162-7.
  478. Skov K, Adomat H, Bowden M, Dragowska W, Gleave M, Koch CJ, Woo J, Yapp DT. Hypoxia in the androgen-dependent Shionogi model for prostate cancer at three stages. Radiation Research 2004 Nov;162(5):547-53.
  479. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. Journal of Clinical Oncology 2006 Jul;24(19):3089-94.
  480. Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, Cook R, Higano CS. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. Journal of Clinical Oncology 2005 May;23(13):2918-25.
  481. So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World Journal of Urology 2005 Feb;23(1):1-9.
  482. So A, Goldenberg L, Gleave ME. Prostate specific antigen: an updated review. Can J Urol 2003 Dec;10(6):2040-50.
  483. So AI, Bowden M, Gleave M. Effect of time of castration and tumour volume on time to androgen-independent recurrence in Shionogi tumours. BJU International 2004 Apr;93(6):845-50.
  484. So AI, Hurtado-Coll A, Gleave ME. Androgens and prostate cancer. World Journal of Urology 2003 Nov;21(5):325-37.
  485. Sprenger CC, Peterson A, Lance R, Ware JL, Drivdahl RH, Plymate SR. Regulation of proliferation of prostate epithelial cells by 1,25-dihydroxyvitamin D3 is accompanied by an increase in insulin-like growth factor binding protein-3. Journal of Endocrinology 2001 Sep;170(3):609-18.
  486. Sprenger CC, Vail ME, Evans K, Simurdak J, Plymate SR. Over-expression of insulin-like growth factor binding protein-related protein-1(IGFBP-rP1/mac25) in the M12 prostate cancer cell line alters tumor growth by a delay in G1 and cyclin A associated apoptosis. Oncogene 2002 Jan;21(1):140-7.
  487. Springate CM, Jackson JK, Gleave ME, Burt HM. Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models. Cancer Chemotherapy and Pharmacology 2005 Sep;56(3):239-47.
  488. Spurgeon SE, Hsieh YC, Rivadinera A, Beer TM, Mori M, Garzotto M. Classification and regression tree analysis for the prediction of aggressive prostate cancer on biopsy. Journal of Urology 2006 Mar;175(3 Pt 1):918-22.
  489. Stanford JL, McDonnell SK, Friedrichsen DM, Carlson EE, Kolb S, Deutsch K, Janer M, Hood L, Ostrander EA, Schaid DJ. Prostate cancer and genetic susceptibility: a genome scan incorporating disease aggressiveness. Prostate 2006 Feb;66(3):317-25.
  490. Stanford JL, Noonan EA, Iwasaki L, Kolb S, Chadwick RB, Feng Z, Ostrander EA. A polymorphism in the CYP17 gene and risk of prostate cancer. Cancer Epidemiology, Biomarkers and Prevention 2002 Mar;11(3):243-7.
  491. Stanford JL, Ostrander EA. Familial prostate cancer. Epidemiologic Reviews 2001;23(1):19-23.
  492. Stanford JL, Sabacan LP, Noonan EA, Iwasaki L, Shu J, Feng Z, Ostrander EA. Association of HPC2/ELAC2 polymorphisms with risk of prostate cancer in a population-based study. Cancer Epidemiology, Biomarkers and Prevention 2003 Sep;12(9):876-81.
  493. Stangelberger A, Schally AV, Letsch M, Szepeshazi K, Nagy A, Halmos G, Kanashiro CA, Corey E, Vessella R. Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers. International Journal of Cancer 2006 Jan;118(1):222-9.
  494. Stephenson RA, Mori M, Hsieh YC, Beer TM, Stanford JL, Gilliland FD, Hoffman RM, Potosky AL. Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study. Journal of Urology 2005 Aug;174(2):646-50; discussion 650.
  495. Sternberg CN, Krainer M, Oh WK, Bracarda S, Bellmunt J, Ozen H, Zlotta A, Beer TM, Oudard S, Rauchenwald M, Skoneczna I, Borner MM, Fitzpatrick JM. The medical management of prostate cancer: a multidisciplinary team approach. BJU International 2007 Jan;99(1):22-7
  496. Stipetich R, Abel LJ, Anderson RL, Butler WM, Wallner KE, Merrick GS. Nursing considerations in brachytherapy-related erectile dysfunction. Urologic Nursing 2005 Aug;25(4):249-54; quiz 259.
  497. Strother JM, Beer TM, Dreicer R. Novel cytotoxic and biological agents for prostate cancer: where will the money be in 2005? European Journal of Cancer 2005 Apr;41(6):954-64.
  498. Sun X, Chen C, Vessella RL, Dong JT. Microsatellite instability and mismatch repair target gene mutations in cell lines and xenografts of prostate cancer. Prostate 2006 May;66(6):660-6.
  499. Sun X, Frierson HF, Chen C, Li C, Ran Q, Otto KB, Cantarel BL, Vessella RL, Gao AC, Petros J, Miura Y, Simons JW, Dong JT. Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nature Genetics 2005 Apr;37(4):407-12.
  500. Swanson KR, Harpold HL, True LD. Prostate-specific antigen: a clinical and mathematical conundrum. American Journal of Clinical Pathology 2006 Mar;125(3):331-3.
  501. Swanson KR, True LD, Lin DW, Buhler KR, Vessella R, Murray JD. A quantitative model for the dynamics of serum prostate-specific antigen as a marker for cancerous growth: an explanation for a medical anomaly. American Journal of Pathology 2001 Jun;158(6):2195-9.
  502. Swanson KR, True LD, Murray JD. On the use of quantitative modeling to help understand prostate-specific antigen dynamics and other medical problems. American Journal of Clinical Pathology 2003 Jan;119(1):14-7.
  503. Takayama TK, Carter CA, Deng T. Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR. Biochemistry 2001 Feb;40(6):1679-87.
  504. Takayama TK, McMullen BA, Nelson PS, Matsumura M, Fujikawa K. Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 2001 Dec;40(50):15341-8.
  505. Tan C, Cruet-Hennequart S, Troussard A, Fazli L, Costello P, Sutton K, Wheeler J, Gleave M, Sanghera J, Dedhar S. Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell 2004 Jan;5(1):79-90.
  506. Tangen CM, Faulkner JR, Crawford ED, Thompson IM, Hirano D, Eisenberger M, Hussain M. Ten-year survival in patients with metastatic prostate cancer. Clin Prostate Cancer 2003 Jun;2(1):41-5.
  507. Tangen CM, Goodman PJ, Crowley JJ, Thompson IM. Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. Journal of Urology 2004 Feb;171(2 Pt 2):S64-7.
  508. Tennant MK, Vessella RL, Sprenger CC, Sikes RA, Hwa V, Baker LD, Plymate SR. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1/mac 25) is reduced in human prostate cancer and is inversely related to tumor volume and proliferation index in Lucap 23.12 xenografts. Prostate 2003 Jul;56(2):115-22.
  509. Thomas R, True LD, Lange PH, Vessella RL. Placental bone morphogenetic protein (PLAB) gene expression in normal, pre-malignant and malignant human prostate: relation to tumor development and progression. International Journal of Cancer 2001 Jul;93(1):47-52.
  510. Thompson I, Tangen C, Tolcher A, Crawford E, Eisenberger M, Moinpour C. Association of African-American ethnic background with survival in men with metastatic prostate cancer. Journal of the National Cancer Institute 2001 Feb;93(3):219-25.
  511. Thompson IM, Albanes D, Basler JW, Crawford ED, Denis LJ, Djavan B, Fleshner N, Johnson-Pais TL, Klein EA, Kristal AR, Lucia MS, Parnes HL, Piazza GA, Platz EA, Pollock BH, Price DK, Reichardt JK, Tangen CM, Tolcher AW, McMann MC. First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statement. Journal of Urology 2004 Feb;171(2 Pt 2):S3-4.
  512. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA Jr. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute 2006 Apr;98(8):529-34.
  513. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. Journal of the National Cancer Institute 2006 Aug;98(16):1128-33.
  514. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The influence of finasteride on the development of prostate cancer. New England Journal of Medicine 2003 Jul;349(3):215-24.
  515. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. New England Journal of Medicine 2004 May;350(22):2239-46.
  516. Thompson IM, Tangen C, Basler J, Crawford ED. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. Journal of Urology 2002 Sep;168(3):1008-12.
  517. Thompson IM, Tangen C, Goodman P. The Prostate Cancer Prevention Trial: design, status, and promise. World Journal of Urology 2003 May;21(1):28-30.
  518. Thompson IM, Tangen CM. Does prostate volume affect accurate grading of prostate biopsies? Nat Clin Pract Urol 2006 Jun;3(6):298-9.
  519. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005 Dec;294(23):2996-3002.
  520. Thompson IM, Tangen CM, Klein EA, Lippman SM. Phase III prostate cancer prevention trials: are the costs justified? Journal of Clinical Oncology 2005 Nov;23(32):8161-4.
  521. Tiffany NM, Ryan CW, Garzotto M, Wersinger EM, Beer TM. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study. Journal of Urology 2005 Sep;174(3):888-92.
  522. Tiffany NM, Wersinger EM, Garzotto M, Beer TM. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. Urology 2004 May;63(5):934-9.
  523. Tolcher AW, Chi K, Kuhn J, Gleave M, Patnaik A, Takimoto C, Schwartz G, Thompson I, Berg K, D’Aloisio S, Murray N, Frankel SR, Izbicka E, Rowinsky E. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clinical Cancer Research 2005 May;11(10):3854-61.
  524. Tolcher AW, Reyno L, Venner PM, Ernst SD, Moore M, Geary RS, Chi K, Hall S, Walsh W, Dorr A, Eisenhauer E. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clinical Cancer Research 2002 Aug;8(8):2530-5.
  525. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T, Cordon-Cardo C, Pandolfi PP. Pten dose dictates cancer progression in the prostate. PLoS Biol 2003 Dec;1(3):E59.
  526. Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES. Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Research 2004 Mar;64(5):1834-42.
  527. True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, Beer TM, Gelmann E, Datta M, Mostaghel E, Knudsen B, Lange P, Vessella R, Lin D, Hood L, Nelson PS. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America 2006 Jul;103(29):10991-6.
  528. True LD, Buhler K, Quinn J, Williams E, Nelson PS, Clegg N, Macoska JA, Norwood T, Liu A, Ellis W, Lange P, Vessella R. A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49. American Journal of Pathology 2002 Aug;161(2):705-15.
  529. Utleg AG, Yi EC, Xie T, Shannon P, White JT, Goodlett DR, Hood L, Lin B. Proteomic analysis of human prostasomes. Prostate 2003 Jul;56(2):150-61.
  530. Uzgare AR, Kaplan PJ, Greenberg NM. Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Prostate 2003 May;55(2):128-39.
  531. Vasioukhin V. Hepsin paradox reveals unexpected complexity of metastatic process. Cell Cycle 2004 Nov;3(11):1394-7.
  532. Vaughan D, Imperato-McGinley J, McConnell J, Matsumoto AM, Bracken B, Roy J, Sullivan M, Pappas F, Cook T, Daurio C, Meehan A, Stoner E, Waldstreicher J. Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia. Urology 2002 Dec;60(6):1040-4.
  533. Vetto JT, Beer TM, Fidda N, Ham B, Jimenez-Lee R, Schmidt W. Fine-needle aspiration diagnosis of plasmacytoma presenting as breast masses in a patient on estrogen therapy for prostate cancer. Diagnostic Cytopathology 2004 Dec;31(6):417-9.
  534. Wafa LA, Cheng H, Rao MA, Nelson CC, Cox M, Hirst M, Sadowski I, Rennie PS. Isolation and identification of L-dopa decarboxylase as a protein that binds to and enhances transcriptional activity of the androgen receptor using the repressed transactivator yeast two-hybrid system. Biochemical Journal 2003 Oct;375(Pt 2):373-83.
  535. Waghray A, Schober M, Feroze F, Yao F, Virgin J, Chen YQ. Identification of differentially expressed genes by serial analysis of gene expression in human prostate cancer. Cancer Research 2001 May;61(10):4283-6.
  536. Wagner M, Garzotto M, Lemmon D, Eilers KM, Beer TM. Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer. Urology 2005 Apr;65(4):799.
  537. Wagner M, Loos J, Weksler N, Gantner M, Corless CL, Barry JM, Beer TM, Garzotto M. Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. Biochemical and Biophysical Research Communications 2005 Jul;332(3):800-7.
  538. Wallner KE, Merrick GS, Benson ML, Butler WM, Maki J, Tollenaar BG. Penile bulb imaging. International Journal of Radiation Oncology, Biology, Physics 2002 Jul;53(4):928-33.
  539. Waltering KK, Wallen MJ, Tammela TL, Vessella RL, Visakorpi T. Mutation screening of the androgen receptor promoter and untranslated regions in prostate cancer. Prostate 2006 Nov 1;66(15):1585-91
  540. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. Journal of Clinical Endocrinology and Metabolism 2004 May;89(5):2085-98.
  541. Wang R, Xu J, Saramaki O, Visakorpi T, Sutherland WM, Zhou J, Sen B, Lim SD, Mabjeesh N, Amin M, Dong JT, Petros JA, Nelson PS, Marshall FF, Zhau HE, Chung LW. PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Research 2004 Mar;64(5):1589-94.
  542. Wang S, Diamond DL, Hass GM, Sokoloff R, Vessella RL. Identification of prostate specific membrane antigen (PSMA) as the target of monoclonal antibody 107-1A4 by proteinchip; array, surface-enhanced laser desorption/ionization (SELDI) technology. International Journal of Cancer 2001 Jun;92(6):871-6.
  543. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, Liu X, Wu H. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003 Sep;4(3):209-21.
  544. Wang Z, Corey E, Hass GM, Higano CS, True LD, Wallace D Jr, Tisdale MJ, Vessella RL. Expression of the human cachexia-associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexia. International Journal of Cancer 2003 May;105(1):123-9.
  545. Wessells H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L, Herlihy R, Fitch W, Labasky R, Auerbach S, Parra R,  Rajfer J, Culbertson J, Lee M, Bach MA, Waldstreicher J. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 2003 Mar;61(3):579-84.
  546. Winter SF, Cooper AB, Greenberg NM. Models of metastatic prostate cancer: a transgenic perspective. Prostate Cancer Prostatic Dis 2003;6(3):204-11.
  547. Wirtzfeld LA, Wu G, Bygrave M, Yamasaki Y, Sakai H, Moussa M, Izawa JI, Downey DB, Greenberg NM, Fenster A, Xuan JW, Lacefield JC. A new three-dimensional ultrasound microimaging technology for preclinical studies using a transgenic prostate cancer mouse model. Cancer Research 2005 Jul;65(14):6337-45.
  548. Wright JL, Higano CS, Lin DW. Intermittent androgen deprivation: clinical experience and practical applications. Urologic Clinics of North America 2006 May;33(2):167-79, vi.
  549. Wright JL, Lin DW, Dewan P, Montgomery RB. Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer. International Journal of Urology 2005 Nov;12(11):1012-3.
  550. Wright ME, Eng J, Sherman J, Hockenbery DM, Nelson PS, Galitski T, Aebersold R. Identification of androgen-coregulated protein networks from the microsomes of human prostate cancer cells. Genome Biol 2003;5(1):R4.
  551. Wu GJ, Fu P, Chiang CF, Huss WJ, Greenberg NM, Wu MW. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model. Journal of Urology 2005 May;173(5):1778-83.
  552. Wu J, Haugk K, Plymate SR. Activation of pro-apoptotic p38-MAPK pathway in the prostate cancer cell line M12 expressing a truncated IGF-IR. Hormone and Metabolic Research 2003 Nov-2003 Dec;35(11-12):751-7.
  553. Wu JD, Haugk K, Woodke L, Nelson P, Coleman I, Plymate SR. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. Journal of Cellular Biochemistry 2006 Oct;99(2):392-401.
  554. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. Journal of Clinical Investigation 2004 Aug;114(4):560-8.
  555. Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL, Plymate SR. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clinical Cancer Research 2005 Apr;11(8):3065-74.
  556. Xie X, Eberding A, Madera C, Fazli L, Jia W, Goldenberg L, Gleave M, Guns ES. Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models. Journal of Urology 2006 May;175(5):1926-31.
  557. Xu J, Dimitrov L, Chang BL, Adams TS, Turner AR , Meyers DA, Eeles RA, Easton DF, Foulkes WD, Simard J, Giles GG, Hopper JL, Mahle L, Moller P, Bishop T, Evans C, Edwards S, Meitz J, Bullock S, Hope Q, Hsieh CL, Halpern J, Balise RN, Oakley-Girvan I, Whittemore AS, Ewing CM, Gielzak M, Isaacs SD, Walsh PC, Wiley KE, Isaacs WB, Thibodeau SN, McDonnell SK, Cunningham JM, Zarfas KE, Hebbring S, Schaid DJ, Friedrichsen DM, Deutsch K, Kolb S, Badzioch M, Jarvik GP, Janer M, Hood L, Ostrander EA, Stanford JL, Lange EM, Beebe-Dimmer JL, Mohai CE, Cooney KA, Ikonen T , Baffoe-Bonnie A, Fredriksson H, Matikainen MP, Tammela TLj, Bailey-Wilson J, Schleutker J, Maier C, Herkommer K, Hoegel JJ, Vogel W, Paiss T, Wiklund F, Emanuelsson M, Stenman E, Jonsson BA, Gronberg H, Camp NJ, Farnham J, Cannon-Albright LA, Seminara D. A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. American Journal of Human Genetics 2005 Aug;77(2):219-29.
  558. Yamanaka K, Gleave ME, Hara I, Muramaki M, Miyake H. Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model. Mol Cancer Ther 2005 Feb;4(2):187-95.
  559. Yamanaka K, Rocchi P, Miyake H, Fazli L, So A, Zangemeister-Wittke U, Gleave ME. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. BJU International 2006 Jun;97(6):1300-8.
  560. Yamanaka K, Rocchi P, Miyake H, Fazli L, Vessella B, Zangemeister-Wittke U, Gleave ME. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther 2005 Nov;4(11):1689-98.
  561. Yasui Y, McLerran D, Adam BL, Winget M, Thornquist M, Feng Z. An Automated Peak Identification/Calibration Procedure for High-Dimensional Protein Measures From Mass Spectrometers. J Biomed Biotechnol 2003;2003(4):242-8.
  562. Yasui Y, Pepe M, Thompson ML, Adam BL, Wright GL Jr, Qu Y, Potter JD, Winget M, Thornquist M, Feng Z. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. Biostatistics 2003 Jul;4(3):449-63.
  563. Yeung LH, Read JT, Sorenson P, Nelson CC, Jia W, Rennie PS. Identification and characterization of a prostate-specific androgen-independent protein-binding site in the probasin promoter. Biochemical Journal 2003 May;371(Pt 3):843-55.
  564. York TP, Plymate SR, Nelson PS, Eaves LJ, Webb HD, Ware JL. cDNA microarray analysis identifies genes induced in common by peptide growth factors and androgen in human prostate epithelial cells. Molecular Carcinogenesis 2005 Dec;44(4):242-51.
  565. You X, Yu HM, Cohen-Gould L, Cao B, Symons M, Vande Woude GF, Knudsen BS. Regulation of migration of primary prostate epithelial cells by secreted factors from prostate stromal cells. Experimental Cell Research 2003 Aug;288(2):246-56.
  566. Yu D, Jia WW, Gleave ME, Nelson CC, Rennie PS. Prostate-tumor targeting of gene expression by lentiviral vectors containing elements of the probasin promoter. Prostate 2004 Jun;59(4):370-82.
  567. Yu D, Scott C, Jia WW, De Benedetti A, Williams BJ, Fazli L, Wen Y, Gleave M, Nelson C, Rennie PS. Targeting and killing of prostate cancer cells using lentiviral constructs containing a sequence recognized by translation factor eIF4E and a prostate-specific promoter. Cancer Gene Therapy 2006 Jan;13(1):32-43.
  568. Yu EY, Hahn WC. Genetic alterations in prostate cancer. Clin Prostate Cancer 2005 Mar;3(4):220-9.
  569. Yu EY, Oh WK. Neoadjuvant therapy for high-risk localized prostate cancer. Curr Oncol Rep 2003 May;5(3):250-7.
  570. Yu HM, Frank DE, Zhang J, You X, Carter WG, Knudsen BS. Basal prostate epithelial cells stimulate the migration of prostate cancer cells. Molecular Carcinogenesis 2004 Oct;41(2):85-97.
  571. Zecha G, Lin DW, Montgomery RB. The increasing role of CAM in prostate cancer. JAAPA 2004 Mar;17(3):37-40, 43-4.
  572. Zeliadt SB, Etzioni R, Kristal AR. Estimated impact of the prostate cancer prevention trial on population mortality. Cancer 2005 Oct;104(7):1556-7; author reply 1557.
  573. Zeliadt SB, Etzioni RD, Penson DF, Thompson IM, Ramsey SD. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. American Journal of Medicine 2005 Aug;118(8):850-7.
  574. Zeliadt SB, Penson DF, Albertsen PC, Concato J, Etzioni RD. Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. Cancer 2003 Aug;98(3):496-503.
  575. Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology 2004 Dec;64(6):1171-6.
  576. Zeliadt SB, Potosky AL, Penson DF, Etzioni R. Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. International Journal of Radiation Oncology, Biology, Physics 2006 Oct 1;66(2):395-402
  577. Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K, Gleave ME. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clinical Cancer Research 2002 Oct;8(10):3276-84.
  578. Zellweger T, Kiyama S, Chi K, Miyake H, Adomat H, Skov K, Gleave ME. Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model. BJU International 2003 Sep;92(4):463-9.
  579. Zellweger T, Miyake H, Cooper S, Chi K, Conklin BS, Monia BP, Gleave ME. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. Journal of Pharmacology and Experimental Therapeutics 2001 Sep;298(3):934-40.
  580. Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 2001 Jul-2001 Aug;3(4):360-7.
  581. Zhang J, Gao N, Kasper S, Reid K, Nelson C, Matusik RJ. An androgen-dependent upstream enhancer is essential for high levels of probasin gene expression. Endocrinology 2004 Jan;145(1):134-48.
  582. Zhang Q, Jang TL, Yang X, Park I, Meyer RE, Kundu S, Pins M, Javonovic B, Kuzel T, Kim SJ, Van Parijs L, Smith N, Wong L, Greenberg NM, Guo Y, Lee C. Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells. Prostate 2006 Feb;66(3):235-47.
  583. Zhang Q, Yang X, Pins M, Javonovic B, Kuzel T, Kim SJ, Parijs LV, Greenberg NM, Liu V, Guo Y, Lee C. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Research 2005 Mar;65(5):1761-9.
  584. Zhang Q, Yang XJ, Kundu SD, Pins M, Javonovic B, Meyer R, Kim SJ, Greenberg NM, Kuzel T, Meagher R, Guo Y, Lee C. Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle. Mol Cancer Ther 2006 Jul;5(7):1733-43.
  585. Zheng X, Chang RL, Cui XX, Avila GE, Hebbar V, Garzotto M, Shih WJ, Lin Y, Lu SE, Rabson AB, Kong AN, Conney AH. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice. Clinical Cancer Research 2006 Jun;12(11 Pt 1):3444-51.
  586. Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, Chen CS. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. Journal of the National Cancer Institute 2002 Dec;94(23):1745-57.
  587. Zou Z, Zhang W, Young D, Gleave MG, Rennie P, Connell T, Connelly R, Moul J, Srivastava S, Sesterhenn I. Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation. Clinical Cancer Research 2002 May;8(5):1172-7.
  588. Zuhlke KA, Madeoy JJ, Beebe-Dimmer J, White KA, Griffin A, Lange EM, Gruber SB, Ostrander EA, Cooney KA. Truncating BRCA1 mutations are uncommon in a cohort of hereditary prostate cancer families with evidence of linkage to 17q markers. Clinical Cancer Research 2004 Sep;10(18 Pt 1):5975-80.